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ABSTRACT
Multiple sclerosis is a common cause of neurological disability in the young adult, 
but, at present, disease modifying medication may have little, if any, effect upon long 
term clinical impairment. For this reason, there is a continuing need to understand the 
mechanisms that lead to long term disability and -  in the context of clinical trials -  to 
develop reliable surrogate markers of disease progression. It may be especially 
useful to describe the early evolution of abnormality within normal-appearing white 
matter (NAWM) and grey matter; firstly because pathology in early MS may be a 
key determinant of later disability, and secondly because there is only a modest 
relationship between white matter lesion load and clinical impairment. This thesis 
presents a series of studies, investigating NAWM and grey matter abnormality in a 
cohort of patients with early relapsing-remitting MS. A key question was whether 
MRI measures were able to detect accumulating abnormality in NAWM and grey 
matter early in the clinical course. An initial investigation, using Ti relaxation time 
estimation, did not detect strong evidence for a net change over time. Attention was 
therefore turned to the magnetisation transfer ratio (MTR) and results from a series 
of studies, investigating NAWM, grey matter and thalamic MTR abnormalities in 
early relapsing-remitting MS are presented. Of note, a clinically relevant reduction in 
grey matter MTR was apparent, and there was evidence for increasing MTR 
abnormality in the grey matter, NAWM and the thalamus over a two year follow-up 
period. In part three of this thesis, a model for the MT effect is used to estimate two 
underlying MT parameters -  the semi-solid proton fraction (/) and the semi-solid T2 
(T2b) in sixty patients with clinically-definite MS. The aim was to assess the clinical 
relevance of these novel parameters.
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DESCRIPTION OF THESIS
This thesis is divided into four parts.
Part 1 gives an introduction to multiple sclerosis and a number of recent pathological 
findings. The principles of MRI and the theory of magnetisation transfer are 
described. The use of MRI in MS is reviewed and an overview is given describing 
previous studies using magnetisation transfer imaging in MS.
Part 2 describes a series of studies investigating abnormality in the normal-appearing 
white matter (NAWM) and normal-appearing grey matter (NAGM) in patients with 
early relapsing-remitting MS. Patients and controls were imaged serially for up to 
three years in order to investigate the natural history and clinical relevance of early, 
normal-appearing brain tissue abnormality. In all subjects, the magnetisation transfer 
ratio (MTR) and Ti relaxation time were determined; (Ti is related to MTR). 
Baseline T i abnormalities were observed but there was no evidence for a definite or 
consistent change over time. Attention was therefore turned to the study of the early 
relapsing-remitting MS cohort using MTR. Baseline and longitudinal studies using 
NAWM and NAGM MTR histograms are presented and the results suggest that 
NAGM MTR abnormality is clinically relevant (it correlates with the EDSS) and that 
increasing MTR abnormalities are developing in the NAGM and NAWM early in the 
course of relapsing-remitting MS. Finally, data describing changes in thalamic MTR 
are presented, providing evidence for the emergence of thalamic MTR abnormality 
within five years of clinical onset.
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In Part 3, sixty patients with clinically-definite MS were imaged using a novel MT 
sequence. A model for magnetisation transfer is used to estimate parameters that 
underlie the MT effect. These include the semi-solid (macromolecular) proton 
fraction (/) and the T2 of the semi-solid pool (T2b). Data on these parameters are 
presented and discussed.
Part 4 includes a summary of the principle findings and conclusions of the thesis.
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PARTI
INTRODUCTION
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CHAPTER 1 
Multiple Sclerosis
1.1 Epidemiology
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central 
nervous system and is an important cause of neurological disability in the young 
adult. In the United Kingdom, the incidence is approximately 7/100,000 (MacDonald 
et al.y 2000) while prevalence ranges from 87/100,000 in Guernsey to 287/100,000 in 
Orkney (Compston, 1998a). The age of onset peaks between the ages of 25 and 34 
while onset prior to 15 or after the age of 55 is uncommon (McDonnell and Hawkins, 
1998). There is also a clear gender difference and there are approximately two 
females with the condition for every male affected (Compston, 1998/?).
MS is most prevalent in northern Europe, southern Australia, New Zealand, and 
North America but it is much less so in south-east Asia, the Arabian Peninsula and 
Africa. However, within regions, local gradients are also recognized. In Europe, the 
highest prevalence is seen in southern Scandinavia, Germany and the United 
Kingdom while lower rates are seen in southern Europe (Compston, 1998a). These 
regional gradients do not always conform to latitude (as was originally thought); a 
diagonal distribution, for instance, exists in the United States, with highest 
prevalence in the north-west and lowest in the south east (Bulman and Ebers, 1992).
18
1.2 Aetiology
Genetics
The evidence for a genetic susceptibility to multiple sclerosis comes from a number 
of sources. The geographical distribution of the disease, once thought to be indicative 
of an environmental factor, may be better explained by regional genetic differences. 
Genetically distinct racial groups living in the same locality often exhibit differences 
in risk, for instance, the lower prevalence in Wales in those with Celtic origins as 
opposed to those with English surnames (Swingler and Compston, 1988). Twin 
studies reveal that around 25% of monozygotic twins are concordant whereas 
concordance in dizygotic twins is similar to the sibling risk (around 3%) (Mumford 
et al., 1994; Compston, 19986; Ebers et al., 1986). Furthermore, the risk of MS in a 
child with one affected parent is 2% while the risk with two affected parents is about 
14% (Robertson et al., 1997). Conversely, the risk of MS in children adopted by a 
parent with MS is no greater than the background risk (Ebers et al., 1995; Compston, 
19986).
Many studies consistently point towards an association between MS and the human 
leukocyte antigen region (HLA) on chromosome 6 and, in particular, the major 
histocompatibility complex (MHC) class II phenotypes DR15 and DQ6 (Compston, 
19986). In one association study, the relative risk of MS in those homozygous for 
DR15 was found to be 48.5 (Beall et al., 1995). Other genes, including regions 
encoding for T-cell receptors, immunoglobulins and myelin structural proteins may 
also be associated with susceptibility to MS (Compston, 19986). ApoE, conversely, 
may be associated with disease severity (Kantarci et al., 2004).
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Systematic genome screening by groups in the UK, Canada and USA has confirmed 
the importance of the HLA. However, additional regions identified (such as 7p and 
14q in the UK study) have little overlap with the studies from the Americas 
(Compston, 19986). In MS, different genes may be implicated in different 
individuals and so genetic studies may need to delineate this, subdividing on the 
basis of clinical, immunological or genetic aspects (such as DR 15 status) (Compston, 
19986). Although there is no evidence for a single, major susceptibility gene in MS, 
it appears likely that several genes are implicated, each exerting a moderate effect 
(Compston, 19986).
Environmental Factors
There is no evidence to suggest that a specific infection causes MS, although, some 
studies have shown that the risk of a demyelinating episode is higher in the weeks 
following an upper respiratory tract infection (Andersen et al., 1993; Panitch, 1994). 
Studies of childhood illness again fail to implicate a single pathogen, but viral 
infections in late childhood (such as measles, mumps, rubella, and particularly 
Epstein Barr virus (EBV)) may have an effect on those who are otherwise 
predisposed. Some groups have focused on viral isolates including studies of EBV 
(Sundstrom et al., 2004), Human T-Lymphocyte virus, Human Herpes virus (HHV)- 
6 and HHV-8, but without, at present, firm evidence that they have a clear role in the 
pathogenesis. Trauma, surgery, anesthesia and emotional stress have also all been 
studied and, in general there is little to support the view that these have a role in MS 
pathogenesis (Compston, 1998a). A recent study, (Buljevac et al., 2003), reported 
that the risk of a relapse doubled during the four weeks following a stressful life 
event but confirmation of this is now needed. Finally, the potential effect of female
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sex hormones has also been studied, particularly as relapse rate is lower during 
pregnancy and higher in the pueperium (Confavreux et al., 1998). Furthermore, it has 
also been suggested that oestrogens may have a disease modifying effect (Sicotte et 
al., 2002).
Risk to migrants and MS epidemics
Some studies have shown that migrants, emigrating prior to their mid-teens, from an 
area with low MS risk to an area with higher risk, experience an increased incidence 
in comparison to that found in their country of origin. Conversely, those migrating 
after the mid-teens tend to retain the risk associated with the region in which they 
originated (Dean and Kurtzke, 1971; Compston, 1998a). Support for this comes from 
a number of sources, including a comprehensive study assessing MS risk in World 
War II veterans migrating within the United States as part of their military service 
(Kurtzke et al., 1971). In contrast, an epidemiological study in Australia, (Hammond 
et al., 2000) found that a reduction in risk also occurred in older migrants (older than 
their mid-teens), who emigrated from high-risk UK and Ireland to settle in lower risk 
Australia. These results, and the results from other studies (including those 
examining migration to Hawaii and Israel) support the view that the MS risk can be 
modified by relocation, although the protective effects of having a particular 
ethnicity are never entirely lost (Compston, 1998a).
A number of studies have described possible epidemics of MS, for instance on 
Orkney, the Faroes and on Iceland. However, others would argue that these are 
epidemics of recognition (coinciding with the appointment of new neurologists to the
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islands) rather than resulting from the arrival of an exogenous aetiological factor 
(Compston, 1998a).
In summary, although the exact aetiology of MS remains obscure, genetic effects 
(with several or many genes exerting influence) clearly have a role. While no single 
environmental agent has been implicated, a modification of genetic risk by 
environmental factors seems likely.
1.3 Pathology 
Historical Context
The first reports of macroscopic pathology in MS (with descriptions of multiple, 
plaques within the brain and spinal cord) have variously been ascribed to Jean 
Curveilhier (c l841), who also provided some early clinical accounts, and to Robert 
Carswell (1838) (Compston, 1998c). However, in 1863, Rindfleisch gave the first 
/ustopathological account with his description of the loss of myelin within lesions. 
He also described that plaques were centred on blood vessels and that the walls of 
these vessels contained an increased density of small round cells. In 1868 Charcot, 
provided the first detailed neuropathological description of the disease and remarked 
upon the presence of glial scar tissue and demyelination. He even speculated on how 
the loss of myelin could lead to symptoms of the disease and how this could ‘disturb 
the due execution of voluntary movements’ (Charcot via Compston, 1998c). Three of 
the four principle pathological substrates in MS, have therefore already been alluded 
to (demyelination, astrogliosis and inflammatory change) and the fourth, axonal 
pathology, was also commented upon in the early literature (Charcot, 1877; Marburg,
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1906), (Marburg described that, in acute MS, axons were relatively although not 
absolutely preserved).
The Basic Lesion
Lesions are typically sharply demarcated, and are often centred on one or several 
medium sized blood vessels (Lassmann, 1998a). Plaques tend to be distributed 
periventricularly or close to the outer surface of the brain and cord. The hallmark of 
the basic lesion is inflammatory demyelination and this appears to be principally T- 
cell mediated. Inflammatory infiltrates are typified by the presence of both CD8+ 
and CD4+ cells but lower numbers of B cells and macrophages are also consistently 
found (Lassmann, 1998a, 19986). Gliosis is also a key finding (Adams, 1977) and a 
majority of inactive plaques in MS contain a fibrillary network of astrocytic 
processes.
In the rim of chronic lesions, thinly myelinated fibres, (suggestive of remyelination) 
are often seen (Lassmann, 1998a) while shadow plaques (discrete areas of thinly 
myelinated axons with astroglial proliferation) are also commonly demonstrated. It 
has been shown that the latter reflect remyelination (rather than incomplete 
demyelination) and, although remyelination can occur in early disease (Prineas et al., 
1993), the ability of oligodendocytes to remyelinate may diminish with time 
(Lassmann, 1998a).
Of note, recent studies have observed acute axonal damage within active and 
chronic-active lesions (Ferguson et al., 1997; Trapp et al., 1998). (Acute lesions 
have numerous T-lymphocytes and macrophages throughout, while chronic-active
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lesions have few inflammatory cells at the centre but relatively more at the plaque 
border). Ferguson et al. found that the expression of amyloid precursor protein (APP) 
(which can be detected at sites of axonal injury) occurs most prominently in active 
lesions. Furthermore, axon ovoids, stained for antibodies to non-phosphorylated 
neurofilaments were associated with a single axon connection, indicative of axonal 
transection (Trapp et al., 1998). The number of axons transected appears to be 
highest in active lesions, less in the demyelinating border of chronic-active lesions 
and least in their inactive centres. It is noteworthy that axonal transection within MS 
lesions occurs at an early stage in MS, and has been observed within a year of 
clinical onset (Kuhlmann et al., 2002).
Lesions appear to be heterogeneous between patients but active lesions from the 
same patient may be homogenous (Lucchinetti et al., 2000). Four lesion types have 
been identified. In patterns 1 & 2, a T-cell mediated attack on the myelin sheath is 
the hallmark; this occurs either via macrophage released toxins (such as TNF-alpha) 
(pattern 1) or via B-cell mediated antibody release and complement attack (pattern 
2). In patterns 3 and 4, oligodendrocyte cell body degeneration and an absence of 
remyelination are characteristic. In pattern 3, lesions have ill defined borders and are 
not centred on veins; Myelin associated glycoprotein (MAG) is lost and 
oligodendrocyte apoptosis is observed. Interestingly, patients with Balo’s rings 
typically have type 3 lesions. In type 4 lesions, perivascular inflammation is 
associated with oligodendrocyte loss and apoptotic figures are not seen. Lucchinetti 
et al. (2000) did not show a clear association between these lesion patterns and the 
four MS clinical phenotypes. However, there was some evidence that patients with 
established relapsing-remitting or secondary progressive disease exhibited pattern 2
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while those with acute MS had either patterns 1, 2 or 3. Patients with primary 
progressive MS had patterns 2 or 4. Barnett and Prineas, (2004) have recently 
reported on the pathology of acute symptomatic lesions (where patients died shortly 
following the onset of a relapse). In many of these lesions there were very few 
lymphocytes and myelin phagocytes but extensive oligodendrocyte apoptosis and 
microglial activity. It remains unclear whether the differences seen in lesion 
pathology truly reflect pathological disparity between MS clinical subgroups. It is 
possible, for instance, that different lesion pathologies arise at different stages of the 
disease.
Grey matter and the macroscopically normal white matter
While there has been considerable focus on the pathological mechanisms seen within 
white matter lesions, cortical lesions have also been observed. These appear to be a 
consistent feature of the disease (Lumsden et al., 1970; Brownell and Hughes, 1962; 
Kidd et al., 1999; Peterson et al., 2001; Bo et al., 2003a, b) and although grey matter 
lesions are less inflammatory than those in white matter (Peterson et al., 2001; Bo et 
al., 2003a), and are less visible on MRI (Kidd et al, 1999), they are associated with 
axonal and dendritic transection, neuronal apoptosis and demyelination (Peterson et 
al., 2001). Recently it has been suggested that grey matter demyelination could be 
extensive in some patients and a proportion of those examined at post-mortem were 
found to have a generalised subpial loss of myelin (Bo et al., 2003b).
Neuropathological examination of the macroscopically normal white matter has also 
revealed clear abnormalities. These include astrogliosis, microglial activation, patchy 
demyelination and perivascular inflammation (Allen and McKeown, 1979; Allen et
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a/., 2001). However, there is also evidence for axonal loss (Evangelou et al, 2000a, 
ft) and it has been shown that the degree of axonal loss within the corpus callosum is 
related to the regional lesion load (Evangelou et al., 2000ft). A further study 
suggested that small caliber fibres were more susceptible to damage than those of 
larger diameter (Evangelou et al., 2001). Furthermore, there is now evidence (from a 
post-mortem study investigating the cord) that axonal loss within normal-appearing 
tissue may be a factor underlying permanent disability (Bjartmar et al., 2000).
Although axonal injury within lesions, occurring acutely (Trapp et al., 1998), or in 
chronically demyelinated lesions (Komek and Lassmann, 2003), may lead to axonal 
degeneration in normal-appearing tissue, other processes may also play a role 
(Bjartmar et al., 2003). It has been suggested that, later in the disease course, axonal 
and neuronal degeneration could promote the loss of surviving neurons via the 
withdrawal of pre and post synaptic trophic signals (Bjartmar et al., 2003; Compston 
and Coles, 2002); and that this, in turn, could lead to a vicious cycle of neuronal 
injury. It is noteworthy that, in the natural history study of Confavreux et al., (2003) 
the time course between EDSS 4 and 6 was similar among patients. In contrast there 
was much more variability in the time taken to reach EDSS 4. It is possible that, at 
EDSS 4, there is sufficient neuronal injury to allow the vicious cycle to propagate, 
whereas it is the frequency of inflammatory activity (which varies from patient to 
patient) that determines the time taken to reach EDSS 4.
At present, this hypothesis of Bjartmar and others remains unproven but if such a 
process exists, it would imply that the prevention of early axonal injury would be key 
in the treatment of MS. Questions arising might ask: (1) whether white matter lesions
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are the main cause of axonal injury in early MS, or whether other processes are also 
important (such as grey matter demyelination); (2) whether is it possible to monitor 
early axonal damage (in the normal appearing white matter and grey matter) such 
that the effect of therapies can be assessed?
1.4 Immunology.
The immunological mechanisms that are associated with MS pathology are complex 
and are briefly summarized here. Initially, (and for unknown reasons) there may be a 
failure in the regulation of auto reactive anti-myelin T-cells. This results in T-cell 
clonal expansion and entry of the primed T-cells into the circulation (Compston and 
Coles, 2002). Changes in the cerebral endothelia allow the primed lymphocytes to 
migrate into the CNS, particularly via the expression of lymphocyte adhesion 
molecules (and reciprocal changes within the endothelia). The migrating 
lymphocytes activate microglia which, in turn, re-present auto-antigen (bound to 
MHC II molecules) leading to a loop of pro-inflammatory stimulus. Toxic mediators 
are released including nitric oxide (which induces physiological conduction block), 
together with a range of pro inflammatory cytokines (IL2, tumour necrosis factor 
(TNF)-alpha, gamma interferon (IFN) are pro-inflammatory while IL4, IL6 and IL10 
down regulate the immune response). The inflammatory reaction leads to further 
breakdown of the blood brain barrier and a secondary influx of immune cells. 
Damage to the oligodendrocyte via toxic mediators, free radicals, complement attack, 
and myelin phagocytosis, may all lead to myelin loss. Similar processes may also be 
responsible for axonal injury. In particular, nitric oxide has been shown to produce 
axonal damage when conjoined with a high axonal firing frequency; however
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oedema, cytotoxic CD8+ T lymphocytes and glutamate excitotoxicity may also play a 
role (Bjartmar et al., 2003).
1.5 Pathophysiology
There is a complex relationship between the pathology of MS and how this leads to 
the symptoms of the disease. Conduction block arises as a result of demyelination 
and inflammation (the inflammatory mediator, nitric oxide, has been shown to block 
saltatory conduction). Conduction block will give rise to the ‘negative’ symptoms 
associated with MS relapses, including upper motor neuron weakness and sensory 
deficits. Conversely, positive symptoms, for instance paraesthesia, are thought to 
occur as a result of the hyperexcitability of previously demyelinated axons. Recovery 
from a relapse will depend on a number of processes including the reduction of 
inflammation and nitric oxide levels, remyelination, the redistribution of sodium 
channels along the axonal membrane, and cortical plasticity.
However, conduction velocity is often not fully restored following a relapse and this 
accounts for the visual-evoked-potential (VEP) delay observed in patients following 
an episode of optic neuritis (Halliday et al., 1972). A block in conduction velocity 
may also account for the transient symptoms experienced when a patient’s body 
temperature is raised. At higher temperatures, nerve conduction across a 
demyelinated segment will falter and symptoms (such as the visual blurring of 
Uhthoff s phenomenon) will be unmasked.
Although there are a number of mechanisms underlying recovery, the process of 
remyelination may fail for a number of reasons. Astrogliosis may create a physical
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barrier to remyelination (Compston and Coles, 2002), and axonal loss will naturally 
limit myelin repair. It was also once thought that oligodendrocyte precursors were 
depleted in chronic MS, but recent work suggests that such precursors are more 
abundant than once supposed (Reynolds et al., 2002).
Acute axonal transection within lesions may further contribute to any irreversible 
deficit arising from a relapse. Although these axons may undergo Wallerian 
degeneration in early MS (Simon et al., 2000) this does not appear to produce short 
term clinical progression. Such a process, however, may have a delayed clinical 
impact and progressive axonal and neuronal degeneration in late disease are likely to 
be of importance in the development of progressive, irreversible disability.
1.6 Clinical Manifestations & Natural History
The majority of individuals affected by MS (over 80%) initially experience an acute 
attack of neurological dysfunction (most typically affecting the optic nerve, brain 
stem or spinal cord) followed by a period of recovery and remission (Matthews, 
1998). The first attack of demyelination -  (or clinically isolated syndrome suggestive 
of MS) is followed, in many but not all, by further attacks -  indicative of new 
inflammatory demyelinating events. In one series (a 40 year optic neuritis follow-up 
study) the rate of conversion to clinically definite MS was 60% (Rodriguez et al.,
1995).
Relapses can take many forms. A cord episode can result in pyramidal limb 
weakness, sensory loss and dysaethesia, while a brain stem episode can lead to eye
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movement abnormalities, vertigo and ataxia. Optic neuritis typically results in 
painful unilateral visual loss with a central scotoma (Matthews, 1998).
In relapsing-remitting MS, relapses typically evolve over hours or days and resolve 
over weeks to months. Symptoms resolving within 24 hours are not considered to be 
due to a relapse. The relapse frequency varies from patient to patient but initially 
may be about 1.3/year (IFNB MS Study Group, 1993) and this falls with time. The 
degree of recovery from each relapse is also variable but many patients may make 
good recoveries. Despite this, the natural history, in a proportion, is of increasing 
disability, either as a result of incomplete recovery from relapses, or from secondary 
progression. Approximately two-thirds of those with relapsing-remitting MS 
eventually enter the secondary progressive phase, the point of transition usually 
corresponding to EDSS 4.0 (Runmarker and Andersen, 1993). In those with 
secondary progressive MS, relapses are less frequent, and are largely replaced by a 
slow and gradual deterioration in neurological function. This most typically takes the 
form of a progressive spastic paraparesis worsening over many years, although other 
forms (such as a progressively worsening ataxia) are also commonly encountered.
The prognosis of MS has been well described. In natural history studies the median 
time from onset to the use of a unilateral walking aid is -15 years (Weinshenker et 
al., 1989), while the median time to the use of a wheelchair is -25-30 years 
(Confavreux et al., 2003). Life expectancy, however, is only marginally reduced: A 
recent study of Danish patients, diagnosed between 1949 and 1996, revealed that 
survival was approximately 10 years less in comparison to an age matched healthy 
population. However, the probability for survival improved during the study period,
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with a near halving of this 10 year excess mortality (Bronnum-Hansen et al., 2004). 
MS may also follow a benign course and, in a recent series (Pittock et al., 2004), 
17% of patients had an EDSS of 2.0 or less after more than 20 years of follow-up. 
However, approximately 10-15% of MS patients have a progressive course from 
onset (Thompson et al., 1997). Although in primary progressive MS, the time to 
reach EDSS 6.0 is short in comparison to those with relapsing remitting MS (a 
median of 6 years in the study of Runmarker and Andersen, 1993), the rate of 
progression is similar to those who have just entered the secondary progressive phase 
(Thompson et al., 1997; Kremenchutzky et al., 1999).
Confavreux et al., (2003) used natural history data to show that MS patients vary 
widely in the time taken to reach Expanded Disability Status Scale (EDSS) 4.0 
(irreversible limitation of ambulation). A number of factors appeared to influence the 
time taken, one being the nature of the presenting symptoms: those who presented 
with isolated optic neuritis took a median of 14 years to reach EDSS 4.0, while those 
who initially presented with brain stem or long tract signs took between 6 and 10 
years. Other influencing factors were: age of onset (those presenting later reached 
EDSS 4.0 more rapidly); the degree of recovery from relapses; time to second 
neurological episode; and the number of relapses in the first 5 years. Conversely, the 
time taken to progress from EDSS 4.0 to EDSS 6.0 (use of a walking aide) was more 
constant (taking a median of 6 years) and this was not influenced substantially by 
any of the above factors. It has been argued that the initial, unpredictable events, 
(relapses which result from the development of new and multifocal inflammatory 
lesions), are replaced by a more gradual and progressive pathological process later in 
the disease course. The Lyons natural history data may indicate that a critical amount
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of CNS damage (corresponding to EDSS 4.0) is necessary to initiate this self 
propagating, progressive process. The frequency and severity of the early relapses do 
not affect the rate of later progression, although they do effect the time taken to reach 
the critical threshold.
1.7 Diagnosis
In MS, lesions develop at different times and at different sites throughout the CNS 
and, characteristically, the development of new lesions will be disseminated in space 
and time. While this concept is central in the diagnosis of MS, it is of equal 
importance that clinical evidence used in the diagnosis is characteristic of the disease 
and that alternative diagnoses have been excluded. The differential for MS is wide 
and includes a number of other conditions where CNS lesions are disseminated in 
space and time (see Table 1.1a).
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Table 1.1a. The Differential Diagnosis of MS.
Differential Diagnosis of Multiple Sclerosis (or Clinically Isolated Syndromes 
Suggestive of MS)
> Inflammatory Causes:
• Acute Disseminated Encephalomyelitis
• Devic’s Neuromyelitis Optica
• Systemic Lupus Erythematosus
• Systemic Sclerosis
• Primary Sjogren’s Syndrome
• Behcet’s Disease
• Sarcoidosis
• CNS Vasculitis
• Susac’s Syndrome
> Infectious Causes:
• Lyme Borreliosis
• Meningovascular Syphilis
• HIV
• HTLV-1 Myelopathy
> Cerebrovascular Disease
> Paraneoplastic Syndromes
> Hereditary Ataxias and Paraplegia’s
> Leucodystrophies :
• Krabbe’s (adult onset myeloneuronopathy)
• Adrenoleucodystrophy
• Alexander’ s Disease (adult onset)
• Metachromatic Leucodystrophy
> Motor Neuron Disease (Primary Lateral Sclerosis)
> Intermittent symptoms secondary to tumours or vascular malformations.
> Subacute combined degeneration of the cord
> Progressive symptoms due to spinal cord compression, a syrinx or a Chiari 
malformation.
33
Table 1.1b. The Differential Diagnosis of Optic Neuritis.
Differential Diagnosis of Optic Neuritis
o Anterior ischaemic optic neuropathy 
o Compressive causes of optic neuropathy 
o Inflammatory causes (eg sarcoid and CRION) 
o Infective causes eg syphilis, 
o Leber’s optic neuropathy, 
o Central serous choroidoretinopathy 
o Neuroretinitis
Based on these concepts, the diagnostic criteria of Schumacher et al., (1965), Poser 
et al., (1983) and McDonald et al., (2001) have been proposed. Schumacher’s criteria 
relied on the collection of clinical evidence (from history taking and clinical 
examination), providing proof of dissemination in space and time. Provided that 
other aspects of the presentation were consistent with MS and alternative diagnoses 
had been excluded, it was possible to reach a diagnosis of definite MS. In 1983, 
Poser and colleagues published a set of revised criteria whereby information from 
CSF examination and paraclinical investigations (evoked potentials, urological 
assessments and imaging studies) could be substituted for clinical information where 
the clinical information alone did not provide proof of dissemination in space and 
time (see Table 1.2). To establish a diagnosis of clinically definite MS, the criteria 
required that there had been at least two attacks and clinical evidence of at least two 
lesions; (or clinical evidence of one lesion and paraclinical evidence for the other).
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Table 1.2: Poser’s Diagnostic Criteria for Multiple Sclerosis
Diagnosis No. of 
Attacks
No. of 
lesions 
(clinical 
evidence)
Paraclinical 
evidence of 
a lesion
CSF
Clinically Definite MS
2 2
2 1 And 1
Laboratory-supported Delinite MS
2 1 Or 1 +
1 2 +
1 1 And 1 +
Clinically Probable MS
2 1
1 2
1 1 And 1
Laboratory-supported probable MS
2 +
Positive CSF: Intrathecal synthesis of oligoclonal bands or increased IgG index 
Reproduced from Poser et al., (1983)
More recently, new diagnostic criteria (McDonald et al., 2001) have integrated the 
evidence provided by MRI with clinical and paraclinical evidence (VEPs and CSF 
examination). In particular, MRI can be used to demonstrate dissemination in space 
(by the distribution of lesions on T2 weighted images) and dissemination in time (by 
the presence of enhancing lesions or of new T2 lesions). The new criteria allow for 
the diagnosis of MS to be made earlier and, in some instances, after the first clinical 
attack. Furthermore, the McDonald criteria can be applied more readily to those with 
primary progressive MS. (See Table 1.3). The provision of an earlier diagnosis may 
be useful, particularly if it is shown that early treatment prevents later disability 
(although that data is currently lacking). At present, the provision of an earlier 
diagnosis needs to be balanced on a patient by patient basis (particularly as in the UK 
disease modifying treatment is not available for those with clinically isolated 
syndromes). Some patients may seek an early and full explanation for their 
symptoms, while others may not.
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Table 1.3. McDonald’s Diagnostic Criteria for Multiple Sclerosis.
Clinical Presentation Additional Data Needed for MS 
Diagnosis
2 or more attacks, objective evidence 
of 2 or more lesions
None
2 or more attacks, objective evidence 
of 1 lesion
DIS (or >2 MRI lesions consistent with 
MS and unmatched CSF OCB), or 
wait further attack implicating new 
site
1 attack; objective evidence of 2 or 
more lesions
DIT or 2"a attack
1 attack; objective clinical evidence of 
1 lesion
(i)DIS (or >2 MRI lesions consistent 
with MS and unmatched CSF OCB) 
and DIT, or (ii) 2nd attack
Insidious neurological progression 
suggestive of MS
unmatched CSF OCB and:
(i){DIS: [(1) >9 cerebral T2 lesions or (2) 
>2 cord lesions or (3) 4-8 brain plus 1 
cord lesion or (4) abnormal VEP with 4- 
8 brain lesions or (5) abnormal VEP <4 
brain plus 1 cord lesion]. AND DIT} 
or (ii) continued progression for 1 year
DIS: Dissemination in space: Need 3 of the following: (1) 1 Gad lesion or 9 T2 
lesions. (2) >1 infratentorial lesion, (3) > 1 juxtacortical lesion, (4) >3 periventricular 
lesions; one cord lesion can be substituted for one brain lesion.
DIT: Dissemination in time: enhancing lesion on a scan done >3 months after a 
clinical event. If no gad lesion, repeat imaging must show a new T2 lesion or gad 
lesion. If the initial scan is done within 3 months of the clinical event, a scan must be 
repeated >3months later. A new T2 lesion or Gad lesion on this scan will prove DIT. 
OCB: Intrathecal oligoclonal bands (or raised IgG index)
VEP: Visual evoked potentials.
Reproduced from McDonald et al., (2001)
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1.8 Treatment and management
Disease modifying medication -  treatment o f acute attacks
High dose, pulsed methylprednisolone is used for disabling relapses. Intravenous 
steroids hasten the recovery from a relapse (Milligan et al., 1987; Beck et al., 1993) 
but they do not improve the long term outcome (Beck et al., 1993). While a 
comparison between oral conventional-dose and intravenous high-dose 
methylprednisolone did not show a clear difference in MS patients (Barnes et al., 
1985), data from the optic neuritis treatment trial (Beck et al., 1993) suggested that 
high dose intravenous steroids followed by an oral taper was more efficacious in 
comparison to conventional doses of oral prednisone alone. However, high dose oral 
methylprednisolone has recently been shown to be effective in comparison to 
placebo (Sellebjerg et al., 1998).
Symptomatic treatments
A number of treatments are used to ameliorate the symptoms of MS (Compston, 
1998d). Spasticity is common and symptoms may be improved with baclofen, 
tizanidine, dantrolene or gabapentin. Side effects are frequent and sedation or an 
increase in muscle weakness often limits the use of such medication. Recently, 
cannabinoids have been tested in patients with lower limb spasticity and this, when 
assessed subjectively by the patients themselves, was reduced in the treatment arm; 
however no treatment benefit was observed on an objectively measured spasticity 
scale (Zajicek et al., 2003). For more marked spasticity, local botulinum toxin 
injection, intrathecal phenol or the insertion of an intrathecal baclofen pump may be 
of benefit. The urinary symptoms resulting from detrussor hyperexcitability can often
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be improved with an anticholinergic while intranasal vasopressin (DDAVP) may also 
be of help. Intermittent self catheterization is helpful when there is incomplete 
bladder emptying; while, if there is intractable incontinence, use of an indwelling 
catheter can improve the quality of life. Neurological pain, such as trigeminal 
neuralgia or myelopathic pain may respond to carbamazepine, gabapentin or 
amitriptyline, while, for cerebellar tremor, propanolol, clonazaepam or isoniazid may 
be of benefit. Clinical trials have shown that MS fatigue can be improved by 
amantidine (The Canadian MS research group, 1987) or modafinil (Rammohan et al., 
2002).
Neurorehabilitation
A number of studies have investigated the effect of neurorehabilitation in MS 
(Petajan et al., 1996; Kidd and Thompson, 1997; Freeman et al., 1997). Aerobic 
exercise improved mood, fatigue levels and levels of domestic activity (Petajan et al.,
1996), while a 25 day intensive inpatient therapy regime reduced the level of 
disability (but not clinical impairment) in chronic progressive patients in comparison 
to controls on the waiting list (Freeman et al., 1997). Such an improvement may be 
sustained for up to three months following discharge (Kidd and Thompson, 1997).
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Disease modifying medication -  relapse reduction and prevention o f progression
A range of potential MS disease modifying therapies have been assessed in the 
context of double blind randomized placebo controlled trials (Table 1.4).
Table 1.4. Treatments assessed for potential disease modifying effect
MS treatments assessed in double blind randomized placebo controlled trials
Beta interferon la and lb Plasma exchange
Glatiramer acetate Intravenous immunoglobulin
Mitoxantrone Cyclophosphamide
Azathioprine Cyclosporine
Methotrexate Linomide
Cladribine Natalizumab
Currently, beta-interferon (IFNB) and glatiramer acetate are the only disease 
modifying agents licensed for use in the UK. Beta-interferons were first used in MS 
for their possible antiviral properties, but in 1993, a definitive clinical trial revealed 
that IFNB lb produced a significant 31% reduction in relapse rate (IFNB MSSG, 
1993). An improvement in MRI outcomes was also reported (Paty et al., 1993). In 
1996, a comparable reduction in relapse rate was seen with intramuscularly injected 
(IM) IFNB la (Jacobs et al., 1996) while, two years later, similar findings were 
obtained with subcutaneous (sc) IFNB la (PRISMS, 1998). By 1998, a large trial 
also reported that IFNB was of clinical benefit in secondary progressive MS patients 
(European Study Group on Interferon Bib in Secondary Progressive MS, 1998). A 
clear improvement was also seen using MRI end points (Miller et al., 1999), 
however, there was no evidence that IFNB lb slowed the rate of brain atrophy in this 
secondary progressive cohort (Molyneux et al., 2000). Subsequent trials in secondary 
progressive MS have not observed a slowing of disability progression (as measured
40
by the EDSS) in patients treated with IFNB (SPECTRIMS, 2001; Cohen et al., 
2002); (although the later observed borderline evidence for a slowing of disability 
progression as measured by the MSFC). Interestingly, recent data from the ETOMS 
(early treatment of MS) study, (assessing the role of IFNB la in clinically isolated 
syndromes suggestive of MS), revealed that treatment at this stage may have an 
ameliorating effect on brain atrophy (Filippi et al., 2004).
Glatiramer acetate has also been assessed in the context of a phase III clinical trial of 
relapsing-remitting MS and was found to have similar clinical efficacy to IFNB in 
reducing relapse rate by 29% (Johnson et al., 1995). In addition, glatiramer acetate 
produced an improvement with MRI endpoints (Comi et al., 2001). However, it was 
not effective in a large trial in primary progressive MS (Wolinsky, 2004).
Mitoxantrone is occasionally used in the UK, albeit off-license. A phase III clinical 
trial revealed that mitoxantrone therapy reduced clinical progression and 
exacerbation rates in patients with worsening relapsing-remitting and secondary 
progressive MS (Hartung et al., 2002). However, mitoxantrone may be cardiotoxic at 
high cumulative doses and it appears to be associated with a 1 in 500 risk of acute 
leukaemia. Therefore it tends to be reserved for patients with rapidly worsening 
relapsing MS.
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Emerging therapies
Newer therapies are currently being investigated and may emerge in the coming 
years. These include Natazulimab (Tubridy et al., 1999; Miller et al., 2003) and 
Campath-IH (Coles et al., 1999). Natazulimab is a humanized monoclonal antibody 
raised against a4 integrin and blocks the migration of lymphocytes into the CNS. As 
a mediator of immune cell migration, a4 integrin (which is expressed on the surface 
of T lymphocytes) binds to vascular cell adhesion molecule-1 (VCAM-1), and 
mediates the capture and subsequent transfer of T-cells across the vascular endothelia 
(Tubridy et al., 1999). Conversely, Campath 1H is a humanized antibody which is 
raised against the lymphocyte antigen, CD52, and thereby results in lymphocyte 
depletion and immunosupression (Coles et al., 1999).
In a six-month phase II controlled trial of relapsing-remitting and secondary 
progressive MS patients (Miller et a l , 2003), patients treated with Natazulimab had a 
90% reduction in new lesion formation and a 50-70% reduced relapse rate in 
comparison to those treated with placebo. The 90% reduction in lesion formation is 
similar to that seen with Campath-IH (Coles et al., 1999) but superior to the 50-75% 
seen with IFNB (Miller et al., 1999; Paty et al., 1993; Simon et al., 1998). 
Interestingly, despite the marked suppression of inflammatory activity seen with 
Campath-IH, brain atrophy continued in treated patients, while clinical progression 
also continued in those who had high baseline lesions volumes (Coles et al., 1999).
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1.9 Summary
This chapter has given an overview of multiple sclerosis and focused on a number of 
interesting recent advances. Studies have revealed that axons are transected in 
inflammatory lesions; that axonal density is reduced in normal-appearing brain 
tissue; and that grey matter demyelination is a consistent feature of the disease. Some 
studies also suggest that the Wallerian degeneration of axons, transected in lesions, 
may result in the loss of axons in the normal-appearing white matter. Axonal 
degeneration may initially be clinically silent, but in late disease, could underlie 
much of the permanent disability encountered in MS. Once a critical threshold of 
tissue damage has been reached, (corresponding to EDSS 4.0), brain injury may self- 
propagate, possibly because of a loss of trans-synaptic trophic support. In all, early 
changes in MS may have a delayed rather than an immediate clinical effect. 
Questions arising include 1) what are the principle causes of axonal degeneration in 
early disease -  does grey matter demyelination have a role? 2) Can early, clinically 
silent tissue degeneration be monitored, allowing for treatments to be more 
effectively assessed? The next chapter will focus on how MRI techniques might 
investigate these questions.
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The following (Figure 1.1) is a hypothetical scheme that suggests that the monitoring 
of normal-appearing tissue abnormality may provide a more complete assessment of 
factors that lead to later disability:
White Matter Grey Matter Microscopic Lesions or 1°
Lesions Demyelination diffuse abnormality
Conventional
MRI
surrogates 
monitor only 
this
Initially clinically-silent, normal-appearing-tissue 
axonal loss, secondary to the Wallerian 
degeneration of: (i) acutely transected axons or (ii) 
axons lost in chronically demyelinated areas.
? Loss of trophic 
support, leading to 
progressive axonal 
degeneration.
n
V)
Novel 
imaging 
could also 
monitor 
these
Critical
Threshold
Increasing
Progressive
Disability
Figure 1.1. Hypothetical scheme for MS pathogenesis
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CHAPTER 2 
Magnetic Resonance Imaging
2.1 Basic Principles
The physics of nuclear magnetic resonance was first described by Rabi, Purcell and 
Bloch (Bloch, 1946), but it would take 30 years before Lauterbur and Mansfield 
would develop the technique for medical imaging (Lauterbur, 1974; Mansfield, 
1976). Magnetic resonance imaging (MRI) is feasible because atomic nuclei develop 
a nuclear paramagnetic polarization in a constant magnetic field (Bloch, 1946) and, 
in biological tissue, this process includes the protons within water, an effect that has 
particular relevance in medical imaging (Hashemi and Bradley, 1997). In a clinical 
scanner, the static field, (typically 1.5-3.0 Tesla), is produced by the main coil, and 
this is applied parallel to the long axis of the subject (by convention the z-axis). 
While protons align with the static field (Bo), they will also precess (or rotate) about 
Bo at an angular frequency (co), the frequency of the precession depending upon the 
field strength, and the gyromagnetic ratio for the hydrogen proton, (y). This 
relationship is given by the Larmor equation [1].
<»0=?®0 D]
To produce an MR signal, a radio-frequency pulse (Bi), is applied in the transverse 
(x-y) plane, at a frequency that matches co. The resulting resonance produces two 
effects: 1) the protons now precess in phase about Bo and 2) they slowly precess 
about Bi (while continuing to rotate much more rapidly about the Bo axis). This 
additional rotation tips the protons into the transverse plane (x-y) (Figure 2.1).
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Figure 2.1. Protons precess about the B0 field applied in 
the longitudinal (z) axis. The RF pulse (Bi) is applied 
in the transverse (x-y) plane, producing a rotation of 
the protons into this plane.
The MR signal is produced by the synchronous rotation of protons in the x-y plane 
and can be detected by the transmit-receive coil. Following the radio-frequency (RF) 
pulse the precessing protons rapidly dephase, resulting in a decay of the signal (this 
is known as T2 decay). Simultaneously, the spins return to the longitudinal axis, and 
this recovery of longitudinal magnetisation is known as Ti relaxation (see Figure 
2.2). Ti and T2 relaxation times vary between tissues and this forms the basis for 
much of the tissue contrast observed in conventional MRI.
T] and T2 contrast
The scanner settings can be varied to produce a difference in tissue contrast. In spin- 
echo imaging, the echo time (TE) is defined as the time between the 90° RF pulse 
and the echo centre, while the repetition time (TR) is the time between one 90° pulse 
and the corresponding 90° pulse repeated in the next sequence. A short TR will 
provide insufficient time for the longitudinal magnetisation to recover, thus 
providing less magnetisation for the next sequence. A difference in tissue Ti 
relaxation times will result in differences in signal intensity, and a T1 weighted image 
will be produced. A long TE will accentuate any difference resulting from T2 effects, 
thus producing T2 weighting. A short TE and long TR will minimize both Ti and T2
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effects and tissue contrast will mainly result from the proton density of the tissue 
(proton density (PD) weighting).
Figure 2.2. Ti and T2 relaxation.
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time in seconds
T1 recovery of longitudinal 
magnetisation (after it has 
been completely destroyed), 
from tissues with T1 
relaxation times of (a) 500ms 
(upper) and (b) 900ms (lower)
1
0
300
time in milliseconds
T2 decay of transverse 
magnetisation from tissues 
with T2 relaxation times of (a) 
120ms (upper) and (b) 75ms 
(lower)
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Gradients and k-space
The gradients used in MRI allow for an image to be reconstructed. (Gradients are 
magnetic fields that change from point to point, usually in a linear manner). In 2D 
imaging, a slice select gradient (directed along the z-axis, for axial imaging) is 
applied at the time of the excitation pulse. Now, only protons within the slice of 
interest will precess at the Larmor frequency and thus be excited by the RF pulse. 
Next, a phase encoding gradient is directed along the y-axis, shifting the phase of the 
spins depending on their y-axis position. Finally, and at the time of sampling, the 
frequency encoding gradient is applied along the x-axis, altering the frequency of 
spins (and thereby the frequency of the signal they produce) in a manner dependent 
on their x-axis position.
The data are collected in a data format known as k-space (the data in k-space have 
been algebraically manipulated so that they are in the spatial frequency domain). To 
successfully reconstruct the image, the phase encoding gradient alters every TR and a 
slightly different signal fills each line of k-space. To acquire an image with a 
256x256 matrix, it is necessary to fill 256 lines of k-space (provided that the number 
of excitations (NEX) =1), and this requires 256 TRs. Each line of k-space contains 
information from the whole slice and to decode this, using the spatial information 
provided by the phase and frequency encoding gradients, a 2D Fourier transform is 
performed. Essentially, the Fourier transform extracts information from complex 
wave forms, providing information about the amplitude and frequency of the signal. 
The signal intensity in each voxel can then be determined using the spatial 
information provided by the gradients.
48
The conventional spin echo (CSE) sequence uses many of the components mentioned 
above (see Figure 2.3). The sequence includes a slice-select, a phase-encoding and a 
frequency-encoding gradient together with a 90° excitation pulse. In addition, a 180° 
refocusing pulse is applied, inverting the direction of spin and refocusing the signal
at TE. The effect of the 180° pulse is to minimize T2* decay effects resulting from Bo 
inhomogeneity, leaving only the effect of spin-spin interaction.
Figure 2.3. Conventional spin echo pulse sequence
phase
encoding
frequency 
encoding
-------------------------------------------------- A /V -----------
Imaging time can be reduced with the use of fast spin echo (FSE). With FSE, 
multiple 180° refocusing pulses are applied during every TR, (together with multiple 
phase encoding gradients prior to each 180° pulse). In this way, several lines of k- 
space can be filled during one TR, and imaging time can be reduced by a factor equal 
to the echo train length (the number of echoes per TR).
90*
RF --------- —
slice select
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Gradient echo (GE) sequences also allow for fast imaging. In GE imaging, the 90° 
pulse is replaced by a pulse that produces a smaller flip angle, reducing the time 
needed for recovery of the longitudinal magnetisation. This allows TRs to be shorter 
and for imaging time to be reduced. However, GE sequences do not include a 180° 
refocusing pulse and, therefore, GE images are prone to susceptibility artifact.
The decreased imaging time afforded by GE is also useful in 3D imaging. Here the 
slice select-gradient is replaced by an additional phase-encoding gradient which is 
employed along the z-axis. Lines in k-space contain data from the whole three 
dimensional matrix and are then reconstructed using a 3D Fourier transform.
Finally echo planar imaging also allows for images to be acquired rapidly. To 
acquire an echo planar image, the frequency encoding gradient is rapidly cycled back 
and forth while the phase encoding gradient is applied as a series of blips. This traces 
out a trajectory in k-space and, by acquiring multiple echoes during this time, k- 
space can be filled in a single TR. This allows images to be acquired very rapidly, 
although image quality is significantly reduced in comparison to spin-echo or 
gradient-echo imaging.
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2.2 The theory of magnetisation transfer imaging
The magnetization transfer (MT) effect was first described by Wolff and Balaban 
(Wolff and Balaban, 1989). MT provides a novel form of tissue contrast and provides 
an indirect assessment of the semi-solid content of tissue. Macromolecular protons 
and protons within phospholipid bilayers are both semisolid, and thus are motionally 
restricted in comparison to water. Such protons will have a rapid T2 decay 
(approximately 10'5 s) and the rapid loss of signal makes it impossible to directly 
detect them with MRI. However, motionally restricted protons have broad absorption 
line shapes (Figure 2.4) and will absorb energy at frequencies not included within the 
narrow line shape of water. In conventional MRI, the frequency of the RF pulse must 
match the resonant frequency of free water; (an off-resonance pulse will fail to excite 
the free water pool and an MR signal will not be obtained). With MTI, an additional 
pulse is included (with a frequency off-set from water resonance), and this semi- 
selectively excites the semi-solid pool while having little direct effect on free water 
(see Figure 2.4).
Figure 2.4. Water and semi-solid absorption rates for a range of RF frequencies.
absorption
on-resonance pulse used for imaging 
(in MTI and conventional MRI)
additional off-resonance 
pulse used in MTISemi-solid pool
RF frequency
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Following the off-resonance pulse, magnetisation is exchanged between the pools, 
resulting in a reduction of the ffee-water longitudinal magnetisation. This produces a 
saturation effect upon the image and a reduction in the signal intensity for any given 
voxel. The greater the semi solid content of the tissue, the greater the saturation 
effect, and this can be quantified using the MT ratio (MTR):
MTR = [Mq -  M s ] /M 0 x 100 percent units (pu) [2]
The absolute MTR values obtained will depend upon the amplitude and off-set 
frequency of the off-water-resonance pulse (as well as upon other scanner settings) 
(Berry et al., 1999). A comparative multi-centre study, investigating healthy control 
subjects on six different scanners, found that cerebral white matter MTR values 
varied between 10 and 50 pu (Berry et al., 1999). Results, however, are much more 
consistent if the imaging is performed using the same sequence and the same imager. 
In a normative study of 41 healthy subjects, (Silver et al., 1997a), data was obtained 
using an interleaved spin-echo MT sequence, (Barker et al., 1996), and white matter 
MTR values ranged between 37.6 pu and 40.6 pu. An earlier normative study, 
(Mehta et al., 1995), investigated 68 healthy volunteers (using a different MT 
sequence), and found that white matter and grey matter MTR values were 36 pu and 
28 pu respectively.
M0 : Signal intensity without MT presaturation. 
Ms : Signal intensity with MT presaturation.
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In the CNS, phospholipid bilayers are likely to make up a significant component of 
the semi-solid pool and reductions in myelin and axonal density will therefore result 
in a reduced MTR. Support for this comes from a number of sources:
• In MS brain at post mortem, MTR correlates with myelin and axonal density 
in lesions and in the normal-appearing white matter (Schmierer et al., 2004a; 
vein Waesberghe et al., 1999). The correlation, however, between axonal 
density and MTR may be secondary to the strong underlying association 
between myelin and MTR (and between myelin density and axonal density) 
(Schmierer et al., 2004a). MTR also correlates with myelin and axonal 
density in the cord (Mottershead et al., 2003).
• Although a number of studies involving animal models have shown that 
inflammation alone can result in small MTR reductions (Dousset et al., 1992; 
Gareau et al., 2000; Stanisz et al., 2004a), it appears that the most marked 
reductions are seen with demyelination and axonal loss (Dousset et al., 1992, 
1995, 1997; Lexa et al., 1994; Kimura et al., 1996; Silver et al., 1996). These 
studies are summarized in Table 2.1 over. The in-vivo studies in MS patients 
will be covered later.
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Study Subject Group or Model Findings
Dousset et al., 1992 Experimental allergic encephalomyelitis Small MTR decreases with oedema
Lexa et al., 1994 Feline model for Wallerian degeneration MTR reductions corresponded to areas of 
myelin degradation
Dousset et al., 1995 Lysolecithin induced demyelination in primates Marked MTR reductions found in areas of 
myelin and axonal loss
Kimura et al., 1996 Porcine model of brain trauma MTR reduced in areas of pathologically 
proven axonal damage
Silver^ al., 1996 A patient with central pontine myelinolysis MTR reduced in the demyelinated pontine 
lesion.
Dousset et al., 1997 HIV positive patients with radiological evidence for 
progressive multifocal leukencephalopathy (PML)
Markedly reduced MTR in the 
demyelinating lesions of PML
Gareau et a l, 2000 Experimental allergic encephalomyelitis Reductions of MTR were reversed with 
suppression of inflammation
Stanisz et al., 2004a Rat sciatic nerve model of inflammation without demyelination MTR reduced by inflammation
2.3 Quantitative models for MT
While MTR may be a useful measure, sensitive to a number of pathological changes 
that occur in MS, and appears to show a semi-specific link to myelin, it is not 
completely specific for any single pathological change. MTR, however, is a 
composite measure, which depends upon a number of more fundamental parameters 
(including the relative size and T2 values of the semi-solid and free-water pools, and 
the rate of cross-relaxation between them); and the estimation of such parameters 
may yield additional pathological insight. Hypothetically, a particular pathology may 
exhibit a characteristic pattern of parameter abnormality, allowing the nature of 
pathological change to be determined. Furthermore, as these parameters are absolute 
measures, they also have the potential to be less dependent on scanner and 
acquisition parameters, making comparisons between studies more straightforward.
To estimate fundamental MT parameters it is necessary to derive a model for the MT 
effect, and a number have been proposed. The original models, (Henkelman et al., 
1993; Morrison and Henkelman, 1995), described systems where continuous 
saturation powers were applied. More recently, models have been developed that 
describe the situation on a clinical imager, where off-resonance irradiation must be 
applied as a series of MT pulses (Sled and Pike, 2000, 2001, Yamykh, 2002; 
Yamykh and Yuan, 2004; Ramani et al., 2002; Tozer et al., 2003; Tofts et al., 2005). 
The model used in the present work (Ramani et al., 2002; Tozer et al., 2003; Tofts et 
al., 2005), is based on that of Henkelman et al., (1993) and Henkelman’s model will 
therefore be discussed in detail here.
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Henkelman based his model on two proton pools: the free water and semi-solid pool, 
(see Figure 2.5) and mathematically described the magnetisation of the two pools 
with sets of coupled Bloch equations (see below).
Figure 2.5: Binary spin bath m odel
M0a and M0b :the size o f  the free and sem i-solid  pools
Mza and Mzb rem aining longitudinal magnetisation for the free and sem i-solid  pools 
Ra and Rb: free and sem i-solid  longitudinal relaxation rate constants 
R: rate o f  cross relaxation,
Rrfa and R ^: absorption rate constants o f  the free and sem i-solid  pool
The model includes a cross-relaxation rate (R) and the following terms for both 
pools: longitudinal relaxation rates (Ra and Rb), absorption rates (Rrfa and R^b), 
native magnetisations (Moa and Mob) and longitudinal magnetisations (M za and M zb). 
Factors that contribute to the absorption rates (Rrfa and Rrfb) include the amplitude 
(co) and off-set frequency (A) of the continuous MT power (ie of the off-resonance Bi 
field), and the T2 of the free and semi-solid pools respectively (T2a and T2b). 
Henkelman normalized his experiment by setting Moa = 1. The system can be
R
M0a M0b
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described with six coupled Bloch equations, giving the time derivatives for the 
magnetisation in the x, y and z planes, for both the free and semi-solid pools. If 
applied at off-resonance, Bj exerts its effect at an angle off-set to the x-y plane 
(Bloch, 1946) and the magnitude of the x-y component of the Bj vector will be 
proportional to coj/y (since Bi = coi/y) while the z component of the Bj vector will be 
proportional to the RF offset: 27tA/y. Bloch equations take the general form: dM/dt 
=y(M x B) and the y in the Bi terms will therefore cancel (leaving coi and 27iA). The 
equations used here describe the situation in the rotating frame, (Bo effects are 
therefore ignored), but they also include cross relaxation terms (with R), Ti effects 
(with Ra or Rb) and T2 effects (with T2a and T2b).
dM.
dt
dM ,b
= R.{m ;  - M ; ) - R M bM 2 ‘ +RMa“M b + a>tM ° [3]
= R„ (a/0* - M b) -  RM0‘M ,  ‘ +RM0bM /  + mtM  b [4]
dt
dM ° M °
dt Ti,
-  2ttAM “ [5]
dM' M' -2 x& M b [6]
dt Tn
dM;  m ;
+ 2nbM " -  co.M° [7]
dt T2a * ' 1
d M b M b
f + 2 x M b - a > , M b [8]
dt Tit
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Assuming that the system reaches steady state, the six time derivatives will equal 
zero. Equations [5-8] can then be re-arranged to eliminate My and Mx, and [3,4] can 
be solved for Mza , (recalling that Moa = 1):
RbRM 0 + R,flRa + RbRa + RaR 
+ Rrfa + RM 0b l R b +  + R ) - R 2M 0‘
[9]
where:
O -  ^2a n CO\ 'Rib no 111
*  i+ ( 2M r2J 2 *  i+ ( 2M r;i)2
Rrfa and Rrfb describe Lorentzian line-shapes for the free and semi-solid pools, (a line- 
shape in this instance is the rate that the pools absorb RF irradiation for any given 
off-set). Henkelman, however, found that the accuracy of his model could be 
improved by using a Gaussian line shape for the semi-solid pool while retaining the 
Lorentzian line shape for free water. Although Henkelman substituted a Gaussian 
line shape for Rrfb, other line-shapes including the superLorentzian (Morrison and 
Henkelman, 1995) may be more appropriate for biological tissue (See part 3 for more 
details).
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Equation [9] can be simplified by noting that (27iAT2a)2 »  1, re-substituting the 
Lorentzian term for Rrfa and dividing by Ra.:
This MT model is now close to the actual model used in the present work (as can be 
seen by comparing equation [12] with the model used in Chapter 7 of this thesis). 
The modifications made by Ramani et al., (2002), Tozer et al., (2003) and Tofts et 
al., (2005) allow the model to be applied to a pulsed MT sequence, and these 
modifications are expanded on in Part 3.
Henkelman normalized his experiment by setting Moa = 1. In these circumstances, 
Mza will equal 1-MTR and, if 1-MTR is plotted against off-set-ffequency, a set of ‘Z- 
spectra’ are obtained; (each Z-spectrum corresponds to a separate MT-power 
amplitude) (Figure 2.6). The shape of the Z-spectra, derived from a particular tissue 
will depend upon the fundamental properties of the tissue, including the relative size 
of the semi-solid pool (M0b), the rate of cross relaxation between the two pools (R), 
and the motional restriction of the semi-solid protons (T2b - obtained via R^b). 
Differing pathologies may have different patterns of parameter abnormality, 
hypothetically allowing pathological processes to be distinguished.
[12]
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In vivo parameter estimation can then be achieved by acquiring a number of data 
points, each acquired using a unique MT-power offset-frequency - amplitude 
combination. For each data point, the MTR is measured within a region of interest 
and a least-squares fitting technique is used to fit the model to the data. Estimates of 
the fundamental parameters can then be derived.
Figure 2.6. Z spectra obtained for three MT pulse amplitudes. As the offset of the 
MT pulse increases, saturation diminishes (and 1-MTR approaches 1). The steep 
portion of the curve relates to direct water saturation, whereas the shoulder 
relates to the indirect saturation of water via the semi-solid pool (ie the MT effect).
Z Spectra
1
1-MTR
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Offset Frequency in Hz
— — low amplitude
intermediate 
amplitude
high amplitude
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Figures 2.7a (above) and 2.7b (below). Fitting the model to data obtained from an 
MS white matter region of interest (reproduced from Davies et al., 2003) (see text 
below for explanation). A Gaussian line shape has been assumed for the 
absorption line shape of the semi-solid pool.
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1-MTR
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offset frequency/ Hz
Curves corresponding to 3 MT pulse amplitudes
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Figure 2.7 provides an example of curve fitting. To illustrate this, Mob (the size of 
the semi-solid pool) is increased while other parameters are kept constant. The upper 
Z spectra (Figure 2.7a) reflect a scenario where the semi-solid content of tissue is 
zero ( M o b = 0). In this case, the only effect that the MT power can have is to directly
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saturate the free water, a phenomenon that only occurs if the MT RF is close to water 
resonance. The Z-spectra are therefore steep and the saturation effect rapidly 
diminishes with increasing RF off-set. Furthermore, when M0b = 0, the Z spectra 
describe the Lorentzian line-shape of free water and are analogous to the water line- 
shape illustrated in Figure 2.4. As the semi-solid concentration increases (Figure 
2.7b), the curve develops a shoulder at high off-sets an effect resulting from the 
magnetisation of the semi-solid pool, and an indirect effect on water. The broadening 
of the line shape at high offsets is analogous to the broad semi-solid line shape 
illustrated in Figure 2.4.
In this example, the model has been fitted simply by altering Mob, but, in reality, all 
parameters within the model (including T2b and R) will also have an effect on the 
spectral shape and are estimated during the least squares fitting.
One simple reformulation used by our group is the derivation of the parameter f  This 
is the fraction of tissue which is semi-solid and is defined a s /=  Mob/( Moa +  Mob). 
Whether patterns of change in f  T2b and other underlying MT parameters could 
distinguish between the differing pathological processes in MS, or be more specific 
for the imaging of myelin, are questions that are asked in part three of this thesis.
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2.4 The use of MRI in the study of multiple sclerosis
2.4.1 Conventional MRI
The first MRI studies of multiple sclerosis (Young et al., 1981; Bailes et al., 1982) 
revealed that the technique was particularly sensitive for the detection of MS lesions. 
Lesions are visible on T2 weighted imaging (Bailes et al., 1982) and these correspond 
to MS plaques at post mortem (Stewart et al. 1984; Ormerod et al. 1987). MRI 
allows for disease activity to be assessed: acute inflammatory lesions will enhance 
with gadolinium (whereas chronic lesions typically do not) (Grossman et al., 1986; 
Katz et al., 1993), and an indication of the extent of the disease can be obtained by 
measuring the total volume of lesions on T2 weighted images (IFNB MSSG, 1995). 
MRI has therefore been used to monitor the effect of treatment (Miller, 2002) and to 
study the natural history of the disease.
Diagnosis o f MS
MRI is invaluable in the diagnosis of MS and a number of diagnostic criteria, 
integrating the information provided by MRI, have been devised (Paty et al., 1988; 
Fazekas et al., 1988; Barkhof et al., 1997; McDonald et al., 2001). The current 
guidelines of McDonald et al., (2001) (See Chapter 1 for details) may be particularly 
sensitive and specific for the diagnosis of MS (Dalton et al., 2002).
T2 lesions and the prognosis following a clinically isolated syndrome
Studies have also shown that prognostic information can be provided by MRI. The 
presence of brain lesions at the time of a clinically isolated syndrome (CIS) 
suggestive of MS indicates that there is an increased risk for the subsequent
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development of clinically definite MS. One study (O’Riordan et al. 1998) showed 
that the risk of MS, ten years following a CIS, was 83% in those with an abnormal 
brain MRI at baseline but only 11% in those with normal brain imaging.
Early changes in T2 lesion load and disability
Conventional MRI has also provided an invaluable insight into the pathological 
mechanisms that occur in MS. The accrual of lesions (on T2 weighted imaging), early 
in the disease course, has a greater impact on long term disability than the 
accumulation of lesions later. A study investigating a cohort of CIS patients (Sailer et 
al, 1999) showed that increases in lesion volume during the first five years, 
correlated well with changes in disability during that period. However, increases in 
lesion volume, in the subsequent five year period, correlated relatively poorly with 
changes in disability over that time. At 14 years, the change in lesion load over the 
first five years was the best predictor of long term disability (r = 0.61) (Brex et al., 
2002).
Gadolinium enhanced imaging
Gadolinium (Gd), chelated to diethylene-triamine-pentacetic acid (Gd-DTPA) is used 
as a contrast agent in MRI. Gadolinium shortens the Tj relaxation time of 
surrounding water protons and the presence of Gd will manifest as a bright 
hyperintensity on Ti weighed images. Gadolinium is intravenously injected and 
therefore the breakdown of the blood-brain-barrier, (a process known to occur in 
acute MS lesions), will result in Gd enhancement (Bruck et al., 1997). Most new 
lesions enhance, (Lai et al., 1996), including newly symptomatic lesions (Miller et
al., 1988). However, enhancing lesions occur within the brain five to ten times more
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frequently than clinical relapses (Miller et al., 1988). Although the predictive value 
for disability is poor (Kappos et al., 1999), Gd enhancement is a useful measure of 
disease activity and has been used widely in MS clinical trials (Miller, 2002).
T] hypointense lesions
A proportion of lesions remain hypointense on Ti weighted images following 
cessation of Gd enhancement (Bagnato et al., 2003). Lesions which are persistently 
hypointense, (as opposed to lesions with less marked Ti abnormality), are associated 
with a reduced N-acetyl-aspartate concentration (Brex et al., 2000a; van Walderveen 
et al., 1999) and reduced axonal density (Bruck et al., 1997; van Waesberghe et al., 
1999). Some studies have shown that there is a stronger correlation between T\ 
lesion load and the EDSS than between T2 lesion load and the EDSS (van 
Walderveen et al., 1995; Truyen et al., 1996).
Conventional M RI o f the spinal cord
Imaging of the spinal cord in MS may also be important, particularly as the cord may 
be the only region of the CNS were lesions are detected (Thorpe et al., 1996a). Cord 
lesions are more commonly found in the cervical as opposed to the thoracic cord 
(Kidd et al., 1993) and new cord lesions, (as opposed to new brain lesions), are more 
likely to cause a relapse (Thorpe et al., 19966). Furthermore, diffuse signal change 
within the cord is associated with disability (Nijeholt et al., 1997).
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2.4.2 Novel Imaging Measures in MS
While conventional MRI has been of considerable use in the study of MS, it should 
be noted that brain lesion load (as calculated using T2 weighted imaging) appears to 
account for -  at most - a third of the variability in clinical status (Brex et al., 2002; 
Molyneux et al., 2001). The modest correlation between disability and lesion load 
may partly be explained by the pathological heterogeneity of lesions (Barnes et al., 
1991; Brex et al., 2000; van Walderveen et al., 1999) and by their varying 
anatomical distribution (Hickman et al., 2001). However, abnormality within 
normal-appearing tissue may also contribute to disability. Focus has therefore turned 
to the investigation of lesions and normal appearing tissue using a number of 
quantitative MR parameters. Novel MRI techniques include: the measurement of 
brain and cord atrophy, MR spectroscopy (MRS), diffusion tensor imaging (DTI), T1 
relaxation time measurement, and magnetisation transfer imaging.
Atrophy
In relapsing-remitting MS, brain atrophy occurs at a rate greater than that seen in the 
normal healthy population (Losseff et al., 1996a; Rudick et al., 1999; Simon et al., 
1999; Fox et al., 2000; Ge et al., 2000; Chard et al., 2004). Loss of brain volume 
affects both grey matter and white matter, and grey matter atrophy is already present 
at a very early stage of the disease (Chard et al., 2002a; De Stefano et al., 2003; 
Dalton et al., 2004). Of note, measures of brain atrophy may make a reliable 
surrogate for axonal/neuronal loss, particularly as 46% of white matter volume 
consists of axons whereas only 24% consists of myelin (Miller et al., 2002). 
Furthermore, atrophy measures are associated with disability (Kalkers et al., 2001).
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Early changes in lesion load have been associated with subsequent brain volume loss 
(Chard et al., 2003), but the modest correlation suggests that lesions are not the only 
factor resulting in global volume changes (Kalkers et al., 2002).
A number of studies have also demonstrated the presence of cord atrophy in MS 
patients and an association between cervical cord volume and disability has been 
observed (Hickman and Miller, 2000). A semi-automated technique, measuring 
cervical cord volume from fast-spoiled gradient echo images, has proven particularly 
reproducible (Losseff et al., 1996). Studies using the technique found a good 
correlation between cord cross-sectional area and disability (Losseff et al., 1996) and 
that cord atrophy progressed over time (Stevenson et al., 1998).
Ti relaxation time
Ti relaxation is abnormally prolonged in MS normal appearing white matter (Miller 
et al., 1989; Kesselring et al., 1989; Barbosa et al., 1994; Haughton et al., 1992; 
Larsson et al., 1998), although the abnormality may partly be due to the contribution 
from microscopic lesions (Barbosa et al., 1994). Measuring Ti globally (with 
relaxation times from numerous voxels represented as a histogram) could provide a 
better assessment of disease burden (Vaithianathar et al., 2002; Griffin et al., 2002a., 
Parry et al., 2002). Ti histogram metrics derived from normal appearing brain tissue 
(Griffin et al., 2002a) and white matter (Parry et al., 2002) have been correlated with 
disability, while Ti metrics from normal appearing white matter correlate with both 
T2 lesion load and atrophy (Vaithianathar et al., 2002). Of note, normal appearing 
brain tissue Ti abnormality was apparent in clinically early relapsing-remitting MS, 
within three years of symptom onset (Griffin et al., 2002a). Furthermore, a recent
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study (Parry et al., 2003) reported that Tj relaxation time in the neocortical grey 
matter and the normal appearing white matter progressively increased in clinically 
definite MS patients followed-up for ~20 months.
MR Spectroscopy
MR spectroscopy (MRS) is a technique that allows for the quantification of 
metabolites in human brain tissue. Each metabolite precesses with a distinct Larmor 
frequency and, by performing a Fourier transform on the free induction decay, a 
spectrum of metabolites can be produced. A number of additional steps are needed 
including suppression of the dominant water peak but, once achieved, the amplitude 
of each peak in the spectrum provides an estimate of metabolite concentration. 
Prominent metabolite peaks from brain tissue include: N-acetyl-aspartate (NAA) (a 
metabolite found exclusively in neurons), myo-inositol, choline, creatine and 
glutamate. Studies of MS using MRS have reported reductions in NAA 
concentration in lesions and NAWM (Davie et al., 1997; Fu et al., 1998; van 
Walderveen et al., 1999); with the latter occurring within three years of clinical onset 
(Chard et al., 2002b). Myo-inositol, a potential marker for glia is elevated in the 
NAWM in CIS suggestive of MS and in early relapsing-remitting MS (Fernando et 
al., 2004; Chard et al., 2002b), suggesting that glial proliferation within NAWM is 
also an early event. In cortical grey matter, NAA and glutamate concentrations are 
also reduced, again at an early stage of the disease (Chard et al., 2002b).
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Diffusion Tensor Imaging
Diffusion tensor imaging (DTI) allows for the characterization of fibre tract integrity 
and anatomy. A diffusion gradient is applied, followed by a 180° refocusing pulse 
and then by a further diffusion gradient. The phase shift produced by the first 
gradient is inverted by the 180° pulse and then refocused by the second gradient. 
Molecules that have diffused during this time will be subjected to a different field 
with the second gradient and, as a result, will not fully refocus. The amount of 
resulting signal loss relates to the distance that molecules have diffused and this can 
be quantified with the apparent diffusion coefficient (ADC). Diffusion imaging can 
also provide information about the preferential direction of diffusion (anisotropy) 
and since diffusion along a nerve fibre tract should be greater than diffusion across 
fibre tracts, fibre tract orientation can be determined. The extent that diffusion is 
anisotropic can be quantified by analyzing the diffusion tensor (a matrix describing 
the diffusion coefficient in three dimensions); and the two most commonly used 
parameters resulting from this analysis are the mean diffusivity (MD) and fractional 
anisotropy (FA). The ADC, MD and FA are sensitive to pathological change in MS 
and the following salient findings have been reported: (1) DTI parameters are 
abnormal in lesions, NAWM and deep grey matter (Cercignani et al., 2000; 
Ciccarelli et al., 2001) and (2) that DTI measures from NAWM correlate with 
disability (Ciccarelli et al., 2001). ADC increases have also been observed in 
NAWM that later develops into a lesion (Werring et al., 2000). However, the 
changes in diffusion characteristics observable within normal-appearing tissues in 
early disease are subtle and difficult to detect (Rashid et al., 2004).
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Magnetisation Transfer Imaging In MS
(i) Early Studies
In the first magnetisation transfer imaging study of MS patients, MTR was found to 
be reduced in MS lesions (Dousset et al, 1992); (the MTR was reduced by ~26%, 
substantially more than the 5-8% seen in the purely oedematous lesions of guinea pig 
experimental-allergic-encephalomyelitis). Significant reductions were also seen in 
the normal appearing white matter (NAWM). The presence of MTR abnormality in 
MS NAWM was later confirmed using a region of interest approach (Filippi et al, 
1995; Loevner et al., 1995). Another, early study reported that mean lesion MTR 
correlated with measures of disability (Gass et a l, 1994).
(ii) MS clinical subgroup studies using whole brain MTR histograms
Histogram analysis, (whereby MTR values from the whole brain are represented in a 
histogram), allows for a global assessment of disease burden. Histogram metrics are 
likely to show increased sensitivity in comparison to measures derived from small 
regions of interest, particularly as histograms may be more effective at detecting the 
subtle abnormalities found within normal-appearing brain tissue (van Buchem et al, 
1996). A number of studies have reported differences between MS clinical subgroups 
using whole brain MTR histograms (Filippi et a l, 1999; Tortorella et al, 2000; 
Dehmeshki et a l, 2001, Traboulsee et a l, 2003). These studies have shown the 
following: (1) patients with benign MS had similar histogram metrics to those with 
clinically isolated syndromes suggestive of MS; and both showed only subtle 
abnormality in comparison to healthy controls; (2) patients with relapsing-remitting 
MS had more marked abnormality than either benign MS or CIS patients; and (3)
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those with secondary progressive and primary progressive MS had more severely 
affected histogram metrics in comparison to those with relapsing-remitting MS. 
Furthermore, a study comparing secondary progressive and primary progressive MS 
patients (Rovaris et al., 2001) found that there was no difference between these 
groups in terms of their MTR histogram metrics, despite the fact that the secondary 
progressive cohort had a higher lesion volume.
(iii) Whole brain MTR histograms are sensitive to change over time 
Measures derived from whole brain MTR histograms are able to detect a progressive 
decline in MTR over time, in patients with secondary progressive MS, relapsing- 
remitting MS or both (Rocca et al., 1999; Patel et al., 1999; van Buchem et al., 
1998). A year-long follow-up study, investigating patients from all MS clinical 
subgroups, revealed that whole brain MTR decreased over time in all types of MS 
and in those with a CIS suggestive of MS (Filippi et al., 2000a). A further serial 
study of CIS patients, (Iannucci et al., 2000), reported the presence of MTR 
abnormality in the normal appearing brain tissue of CIS patients, and that lower 
MTR values were obtained from those who eventually developed clinically definite 
MS. In contrast, similar MTR abnormalities were observed when comparing the 
normal appearing brain tissue of patients who had experienced a recent CIS (~4 
months previously) in comparison to those who had presented with a CIS 14 years 
previously (but who had not subsequently developed clinically definite MS) 
(Traboulsee et al., 2002).
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(iv) MTR histogram metrics correlate with disability in MS
Measures derived from whole brain MTR histograms are associated with disability. 
Studies have shown a relationship with physical disability (van Waesberghe et al., 
1998a; Iannucci et al., 1999; Traboulsee et al., 2003), and with cognitive impairment 
(Rovaris et al., 1998; Comi et al., 1999; Rovaris et al., 2000; Zivadinov et al., 2001). 
The use of principle component analysis (which maximizes the variability between 
histograms), appears to improve the correlation between whole brain MTR and 
disability measures (Dehmeshki et al., 2001).
(v) MTR measures from pre-lesional MS NA WM
A number of serial MTI studies have investigated regions of NAWM which later 
developed into a lesion. Some have shown that the MTR falls in the months prior to 
lesion enhancement (Filippi et al., 1998; Goodkin et al., 1998; Laule et al, 2003); 
while others have not (Silver et al., 1998; Dousset et al., 1998). MTR has also been 
reported to fall prior to the development of a new T2 lesion (Pike et al., 2000). These 
findings suggest that microscopic changes occur within the NAWM prior to the 
marked blood-brain barrier breakdown detected by Gd enhancement. Following 
lesion enhancement, the MTR may either recover (Lai et al., 1997), remain 
depressed, or continue to progressively decline, presumably reflecting heterogeneity 
in lesion pathology and repair (van Waesberghe et al., 19986; Dousset et al., 1998; 
Laule et al., 2003).
72
(vi) MTR measures o f MS normal-appearing grey and white matter 
Recent advances in image analysis software have enabled images to be segmented 
into grey matter and white matter and, therefore, for the investigation of both tissues 
separately. Studies have reported that grey matter MTR is reduced in clinically 
definite MS (Cercignani et al., 2001), and that grey matter MTR abnormality in 
relapsing-remitting MS is related to the EDSS (Ge et al, 2001). Furthermore, grey 
matter MTR abnormality is more marked in those with secondary progressive MS 
than in those with relapsing-remitting MS (Ge et al., 2002). Grey matter MTR 
abnormality has also been observed in patients with clinically isolated syndromes 
suggestive of MS (Traboulsee et al., 2002), and MTR abnormality is also apparent 
within the deep grey matter of such patients (Audoin et al., 2004).
Furthermore, studies (using measures derived from small regions of interest) have 
revealed the presence of NAWM MTR abnormality (although not grey matter 
abnormality) in minimally disabled patients with early relapsing remitting MS 
(Griffin et al., 20026; De Stefano et al., 2002).
(vi) Predictive value o f normal-appearing brain tissue MTR
Recent evidence suggests that normal-appearing brain tissue MTR abnormality might 
predict future disability. In a longitudinal study, (Santos et al., 2002), NAWM MTR 
values at baseline were related to the change in clinical disability over the subsequent 
five years (r = -0.76). Furthermore, a study of 73 MS patients followed up for a mean 
of 4.5 years (Rovaris et al., 2003) found that the change in whole brain MTR over 
the first year and the baseline T2 lesion load were predictive of medium term 
disability (r2 = 0.23).
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(vii) MTI o f the optic nerves and spinal cord
A number of studies have observed a decline in optic nerve MTR following an 
episode of optic neuritis (Hickman et al., 2004; Inglese et al., 2002; Thorpe et al., 
1995). Following optic neuritis, MTR continues to decline on average for 
approximately 8 months before showing some recovery (Hickman et al., 2004). Of 
note, lower MTR values were observed in those who had a poor visual recovery in 
comparison to those who recovered well (Inglese et al., 2002).
MTR has also been measured in the cervical cord of patients with MS (Silver et al., 
19976). Lower MTR values were observed in those with locomotor disability 
(Bozzali et al., 1999) and those with progressive forms of MS (Filippi et al., 20006). 
The EDSS was also seen to correlate weakly with upper cord MTR (Nijeholt et al., 
2000).
(viii) The use o f MTI in therapeutic trials
Several studies have assessed the effect of MS therapy on MTR. The rate of MTR 
recovery in acute lesions, (following the onset of enhancement), was more rapid 
when patients were treated with steroids (Richert et al., 2001) or IFNB (Richert et 
al., 2001; Kita et al., 2000). However, IFNB had no effect on whole brain MTR, 
either in a IFNB lb crossover trial investigating patients with relapsing-remitting MS 
(Richert et al., 1998); or in a multi-centre, double-blind, placebo-controlled trial of 
IFNB lb in secondary progressive MS (Inglese et al., 2003).
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2.4.3 Surrogate Outcome Measures in MS
There are a number of difficulties in conducting clinical trials in MS using clinical
endpoints alone. Disability in MS develops slowly, typically over decades, and
placebo controlled clinical trials need to run for 2-3 years and recruit several hundred
patients if therapies are to be adequately assessed (Miller, 2002). To assess the effect
of therapy on long term disability further follow-up may be required, (possibly as
part of an open-label study since it may not be feasible to run a placebo controlled 
study for more than 3 years). However, even a long term open label study would be a
major undertaking and it might be useful to assess whether a therapy has potential to
prevent long term disability, prior to embarking on such a study. Surrogate outcome
measures may be helpful in this regard, particularly if they are sufficiently sensitive
to detect treatment effects in small numbers of patients followed up for short periods.
It is essential however, that such measures are predictive of future disability and that
they are accurate, objective and reproducible (Miller, 2002).
A consensus has recently been reached concerning the key requirements needed for 
any MS surrogate (McFarland et al., 2002): Importantly, a surrogate should predict a 
clinically meaningful outcome and it should be sensitive and specific for pathological 
change that leads to later disability.
Ideally, a surrogate would also be sensitive to change over time in early MS, at a 
stage prior to the onset of major disability. (A measure that only detected 
abnormality following the onset of permanent disability would be of little use in 
assessing the effect of therapy on preventing disability).
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In some regards, the measurement of T2 lesion load fulfills the requirements for a 
surrogate: (1) T2 lesion load increases over time in CIS suggestive of MS (Sailer et 
al., 1999), allowing the effects of treatment to be detected (IFNB MSSG, 1995); and
(2) early changes in T2 lesion load are, to a limited extent, predictive of permanent 
disability (Brex et al., 2002). However, in one particularly long follow-up study (14 
years, Brex et al., 2002), changes in T2 lesion load only explained a proportion (~30- 
40%) of the variance in long term disability, raising the possibility that, even with a 
marked suppression of T2 lesion accrual, long term disability could still occur 
(possibly via changes not detected by T2 weighted imaging). Furthermore, there is 
evidence that IFNBs almost completely stabilize T2 lesion volume in secondary- 
progressive MS, but that they don’t prevent an increase in disability (Miller et al., 
1999; SPECTRIMS, 2001).
In Chapter 1, evidence was presented on the existence of pathological abnormality 
within the NAWM and grey matter. By quantifying such changes, and combining 
these with lesion load measures, it may be possible to obtain a more complete 
assessment of the disease. Hypothetically, this may improve the predictive power of 
MRI for future disability allowing therapies to be more effectively assessed. In this 
way, it may be possible to gain some insight into which therapies might potentially 
prevent long term disability (and which therapies should be assessed further using 
clinical endpoints).
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However, it should also be noted that there are a number of additional reasons for the 
modest correlation between T2 lesion load and disability (beyond the fact that grey 
matter and NAWM abnormality may contribute to disability). These include (1) the 
pathological heterogeneity of lesions; (2) the varying distribution of lesions; (3) 
measurement error; (4) the fact that lesions may have different effects on disability 
accumulation at different stages of MS: more so in early relapsing-remitting disease 
and less so during the progressive stages.
Long term natural history studies are therefore needed to ascertain whether grey 
matter and NAWM abnormality contribute to future disability. The early relapsing- 
remitting MS patients studied in this thesis have currently been followed up for ~3 
years and the long term data needed to answer this last question is not yet available. 
However, it has been possible to address an equally important question: whether 
MTR and Ti relaxation time can detect change over time in early MS.
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2.5 Summary
In this chapter, conventional and novel MRI techniques have been reviewed. A 
number of novel MRI techniques (including Ti relaxation time measurement and 
MTR) appear to be sensitive to MS pathology in NAWM and grey matter, even at 
the earliest stages of the disease.
By studying a cohort of patients with early relapsing-remitting MS and minimal 
disability it may now be possible to describe the evolution of the NAWM and grey 
matter change in early MS. It would also be useful to investigate whether such 
changes are clinically relevant. Furthermore, it would be interesting to investigate the 
clinical relevance of parameters (such as/ and T2b) that underlie the MT effect.
With relevance to Chapters 3-8, questions that, at the time of the study, were 
unanswered included:
• Can histogram analysis detect grey matter MTR abnormality in early MS?
• Is grey matter and/or NAWM MTR abnormality in early MS clinically 
relevant?
• Can Ti or MTR histograms detect changes over time in early MS?
• Can MTR abnormality be detected in the deep grey matter?
• Are the underlying MT parameters ( f  and T2b) of clinical relevance in MS?
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PART 2
THE INVESTIGATION OF EARLY RELAPSING-REMITTING
MULTIPLE SCLEROSIS
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CHAPTER 3
Normal appearing grey and white matter Tt abnormality in early relapsing 
remitting multiple sclerosis: a longitudinal study.
In the last chapter, evidence was presented suggesting that the brain T2 lesion load in 
MS might account for a modest proportion - possibly up to a third - of the variability 
in clinical status (Molyneux et al., 2001; Brex et al., 2002). As mentioned, the 
modest correlation may partly arise because lesions are pathologically heterogeneous 
(Barnes et al., 1991; Brex et al., 2000; van Walderveen et al., 1999) and because 
they vary in their anatomical distribution (Hickman et al., 2001). However, 
widespread abnormality - outside of macroscopic lesions - within the brain and cord 
could also contribute to clinical impairment, and measures that quantify this change 
might explain a greater proportion of the variance in disability. Indeed, such 
measures could be of potential use in the assessment of disease modifying therapy, 
(for instance, if they are used as secondary surrogate endpoints in clinical trials).
As mentioned, the T1 relaxation time is a quantitative MR measure that is abnormally 
prolonged in MS normal appearing white matter (NAWM) (Miller et al., 1989; 
Kesselring et al., 1989; Barbosa et al., 1994; Haughton et al., 1992; Larsson et al., 
1998). Furthermore, a number of recent studies have suggested that the global 
measurement of Ti (with relaxation times from numerous brain tissue voxels 
represented as a histogram) could provide a good assessment of disease burden 
(Vaithianathar et al., 2002; Griffin et al., 2002a; Parry et al., 2002). Recently, Parry 
et al., (2003) reported that grey matter and NAWM Ti abnormality increased over
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time in a cohort of secondary progressive and relapsing remitting MS patients 
followed-up for ~20 months.
It should also be noted that whole brain Ti histograms are sufficiently sensitive to 
detect the subtle abnormalities occurring within the normal appearing brain tissue in 
minimally disabled patients with early relapsing-remitting MS (Griffin et al., 2002a). 
A region of interest analysis of the same cohort revealed that Ti was not only 
prolonged in NAWM but was also abnormal in NAGM (Griffin et al, 2002b).
Early change in GM and NAWM may play a role in the development of disability 
(Rovaris et al., 2003; Chard et al., 2002b) and MR techniques that can detect this 
change could potentially be of use as secondary endpoints in clinical trials. In the 
previous chapter, it was noted that, to act as a surrogate endpoint, measures must be 
predictive of a clinically relevant outcome (McFarland et al., 2002) and, ideally, they 
should be sensitive to change over time prior to the onset of permanent disability. 
Therefore, the aim of this study was to assess whether the present technique was able 
to detect increasing NAWM and NAGM T\ abnormality in a cohort of minimally 
disabled patients with early relapsing-remitting MS.
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3.1 Methods.
Subjects
Twenty three patients with early clinically-definite relapsing-remitting MS (Poser et 
al., 1983; Lublin and Reingold, 1996) (Six male and 17 female; mean age 36 years, 
range 24-55 years; mean disease duration at baseline (time from first symptoms): 2.0 
years, range 1.2 to 3.7 years; median expanded disability status scale (EDSS) 
(Kurtzke, 1983) score 1.0, range 0-2.5) were imaged six monthly. At baseline, no 
subjects with MS were taking disease-modifying medication. Fourteen healthy 
controls (seven male and seven female, mean age 35 years, range 27-52 years) were 
also studied. Mean follow up was 26 months for MS subjects (range 6-38 months) 
and 24 months for controls (range 6-36 months).
The study was approved by the ethics committee for the National Hospital for 
Neurology and Neurosurgery, Queen Square, UK. Written informed consent was 
obtained from all subjects.
Magnetic Resonance Imaging
Three sequences were obtained in all subjects: Firstly, a dual-echo fast spin-echo 
(FSE) sequence was acquired for lesion identification (repetition time (TR) 2000ms, 
echo time (TE) 19/95ms, 28 contiguous 5mm axial slices covering the whole brain). 
In addition, proton-density and Ti weighted gradient-echo data sets were acquired for
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Ti estimation. The TR/TE/flip angle/no. of averages for the PD and Ti weighted 
images were 1500ms/llms/45°/8 and 50ms/l lms/45°/2 respectively.
Ti was estimated while accounting for Bi inhomogeneity and an imperfect slice 
profile (Parker et al., 2001). In brief, flip angles vary throughout the thickness of a 
slice, and differ from the nominal flip angle prescribed. Although the prescan 
sequence will adjust the pulse profile, (setting the central portion of the slice to the 
nominal value), flip angles will nonetheless vary with distance perpendicular to the 
slice plane. To obtain a more accurate assessment of the signal contribution from the 
whole slice, Parker et al. (2001) used Bloch simulations to estimate the resultant 
response of the magnetization vector across the 5mm slice thickness (for a range of 
nominal flip angles). Signal contributions could then be integrated across the slice 
profile, providing an estimate of the true total signal (Parker et al., 2001). The coil 
Bi distribution was also determined with the use of a phantom (with uniform proton 
density, Ti and T2), and this data was used to describe how Bi varies relative to the 
centre of the head coil (Parker et al., 2001). With this information, Ti can be 
estimated with the use of a look-up table relating the signal intensity (SI) ratio 
(obtained from the Ti and PD weighted GE data sets) to the Ti relaxation time at any 
given distance from the coil centre. The look-up table’s ratios (namely, the ratio of 
Ti-weighted SI to PD-weighted SI) are calculated, accounting for the slice profile as 
above. (A ratio is used to avoid dependence on scanner gain settings and T2 
weighting). A Ti map can then be produced, using the measured Ti-weighted signal 
intensity and the measured PD-weighted signal intensity, together with knowledge of 
the slice position.
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Image post processing
Following registration of FSE data to the Ti weighted image (using the AIR package) 
(Woods et al., 1993), lesions were contoured on the short echo FSE image using a 
previously described method (Sailer et al., 1999). Segmentation of the Ti weighted 
images into grey matter, white matter and CSF segments was achieved using SPM99 
(Statistical Parametric Mapping, Wellcome Department of Cognitive Neurology, 
Institute of Neurology, Queen Square, London) (Ashbumer and Friston, 1997, 2000). 
A whole brain mask (that excludes CSF and other non-brain parenchyma) was 
generated in SPM99 and then applied to the Ti map. An algorithm, utilizing the GM, 
WM and CSF probability outputs from SPM99, was then used to segment the Ti 
whole brain map into WM and GM matter segments: Voxels were classified as GM, 
WM or CSF depending upon which probability map demonstrated the greatest 
probability at that location. Lesions were excluded from the analysis by setting their 
pixel value to zero, leaving only NAWM and NAGM. Partial volume voxels were 
minimized with a 1000ms threshold for NAWM and a 1700ms threshold for NAGM 
while two successive erosions of WM and a single erosion of GM were performed 
(two erosions of GM resulted in only a few GM voxels remaining). (See the 
Appendix for figures illustrating the segmentation algorithm). Normalized NAWM 
and NAGM histograms were generated with a bin width of 1ms and a smoothing 
window of +/- 5ms. The histogram mean, peak location and peak height were then 
determined.
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Statistical Analysis
Changes in Ti over time were modelled using hierarchical regression (Goldstein, 
1995) with random subject-specific intercepts and a common slope on time. In a 
random intercept - common slope model, a subject-specific intercept is determined 
for each individual while a common gradient is found that best describes the change 
over time in the group of subjects.
For the ith subject at time j, the Ti value (yjj) is given by the following equation:
y„ = (P ^cn  + /? ,) + f K j + S y
where the subject-specfic intercept (pi), and the common gradient (p) are numerically 
determined using a least squares technique (which iteratively minimizes the model 
residuals -  8jj). Essentially, each data point can be described with the equation and 
the sum of ey minimized to find the best estimate for p and the best estimates for pi. 
The mean regression line is given by the mean intercept (pmean) and the common 
slope (p). Models can be adapted to include, for instance, a patient-indicator term (to 
allow patients to be compared with controls) and terms for age and gender.
In the present study, the model used a random subject-specific intercept and common 
slope on time with a time scale with an origin at study baseline. Patient indicator and 
patient x time interaction terms were used to assess patient vs. control differences. 
Terms for age and gender were retained in the final model if they contributed at the 
p<0.1 level. Gender was therefore included in models for NAWM mean-Ti,NAWM 
peak-height and NAWM peak-location, but age was omitted. Both age and gender
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were omitted from the model for NAGM mean-Ti. Age (but not gender) was 
included in the model for NAGM peak-location, while gender (but not age) was 
included in the model for NAGM peak-height. Baseline comparisons between 
patients and controls were estimated using the longitudinal models. The coefficient
of variation (COV) was used as a measure of repeatability (the COV is calculated by 
averaging the intra-subject variance, calculating the standard deviation from this and 
dividing by the mean Tj). A Wilcoxon signed rank test was used to assess serial 
change in the EDS S.
3.2 Results.
Reproducibility
Coefficients of variation (COVs) were calculated using data obtained from the first 
six months of the study (13 controls and 20 patients were included in this analysis as 
other subjects were not imaged at six months). The COVs for NAWM and NAGM 
are given in Table 3.1 below.
Table 3.1 Coefficients of variation in patients and controls
Tissue Parameter COV in 13 COV in 20
controls (%) patients (%)
NAWM Mean Ti 2.7 2.2
Peak Location 3.1 2.5
Peak Height 2.3 5.6
NAGM Mean Ti 2.8 2.1
Peak Location 4.2 2.5
Peak Height 3.1 6.1
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Baseline M RI findings
Mean baseline T2 lesion load was 7.3 ml (median: 4.6 ml, range 0.9 to 26.6 ml). The 
mean-Ti, peak-location and peak-height values are given in Table 3.2 below.
Table 3.2 Baseline T\ values
Patients n = 23 Controls n = 14 P*
NAWM Mean Ti 669 ms (29 ms) 630 ms (23 ms) <0.001
Peak Location 644 ms (28 ms) 610 ms (27 ms) 0.002
Peak Height 0.0082 (0.0009) 0.0088 (0.0008) 0.001
NAGM Mean Ti 1138 ms (40 ms) 1099 ms (24 ms) 0.01
Peak Location 1116 ms (39 ms) 1085 ms (46 ms) 0.2
Peak Height 0.0024 (0.0001) 0.0025 (0.0001) 0.3
*Note that the patient vs. control comparisons are made using the adjusted baseline 
patient-control differences, estimated using the longitudinal models. The model 
baseline differences (see text below) will therefore differ slightly from the crude 
baseline cross-sectional differences.
Compared to controls, the patients’ mean Ti was significantly higher in NAWM 
(mean gender adjusted difference: 29ms; 95% confidence interval (Cl) 14ms, 45ms; 
p < 0.001). In NAWM, males had a slightly higher Tj value in comparison to females 
(mean difference: 15ms; 95%CI 1ms, 30ms, p = 0.04), but when gender was 
excluded from the NAWM model, there was little effect on the patient-control 
difference (mean difference (non-gender adjusted): 33ms; p < 0.001). Peak height 
and peak location from the NAWM Ti histogram were also significantly different 
between patients and controls (gender adjusted patient-control differences: -0.0008;
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95% Cl -0.001, -0.0003, p = 0.001 and 25ms; 95% Cl 9ms, 41ms p = 0.002 
respectively).
In NAGM, mean Ti was also significantly higher in patients than in controls. The 
mean patient-control difference was 26ms; 95% Cl 6ms, 47ms; p = 0.01. There was 
no evidence that NAGM peak height and peak location differed between patients and 
controls.
Longitudinal changes
Clinical follow up
Median EDSS increased from 1.0 (range 0-2.5), at study entry, to 1.5 (range 0-6) at 
the last imaging time point; p = 0.02.
Regression analysis o f serial NA WM and NAGM Tj data
In NAWM and in NAGM, for both the mean T i and the peak location, there was no 
evidence of a serial change over time in patients or controls (See Tables 3.3a and 
3.3b over). (There was also no evidence for a difference in the rates of change 
between patients and controls for either of these parameters). There was weak 
evidence that the NAWM peak height was declining in patients (-0.001 /year, p = 
0.02); and while there was no significant decline in controls (p = 0.4), the patient- 
control rate of change was not significant (p = 0.5). However there was also weak 
evidence that the NAGM peak height was declining in controls (-0.00004 / year, p = 
0.03); the patient-control rate of change was significant (0.00005 / year, p = 0.03); 
but there was no significant decline in patients (p = 0.5).
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Figure 3.1. Individual and group mean Ti values (with 95 % Cl) for MS patients (left) and healthy control subjects (right), from NAGM (upper) 
and NAWM (lower).
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3.3 Discussion
This longitudinal study of clinically early relapsing-remitting MS patients has 
revealed the presence of Ti relaxation time abnormality in both NAWM and NAGM. 
This supports the earlier cross-sectional study of Griffin et al. (2002a) in which Ti 
abnormality was observed in the NABT of MS patients within three years of clinical 
onset. Of note, in the present work, there was no detectable net change in mean Ti 
during the period of study.
There was weak evidence for a decline in NAWM peak height in MS patients, (albeit 
without evidence for a significant patient-control difference). However, there was 
also evidence for a decline in the NAGM peak height in controls, without evidence 
for a change in patients. When considered in conjunction with the COV data, (in 
which the peak-height-COV in patients was found to be high in comparison to other 
parameters), it seems likely that these conflicting peak-height findings may relate to 
the limited reproducibility of the peak height measure. In all, although there was a 
decline in patient NAWM peak height, when this result is considered together with 
the mean and peak location data, there is little overall evidence for a serial change in 
T i .
In MRI, protons excited with a radio-frequency (RF) pulse, rotate from the plane of 
the static magnetic field to later re-align with this plane following cessation of the RF 
power. The Ti relaxation time describes the rate at which protons make this re­
alignment and it is an inherent property of protons and their local environment. 
Various pathological processes are known to affect Ti relaxation time in brain
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parenchyma. Naruse et al. (1982) investigated experimental oedema and found that 
changes in tissue Ti were closely mirrored by changes in tissue hydration, while a 
further study (Barnes et al,. 1988) demonstrated that experimentally induced gliosis 
increased Ti. Others have shown that Ti can be affected specifically by myelin 
content (Fischer et al., 1989, 1990) while, in lesions, the concentration of N-acetyl 
aspartate (a neuronal marker) has been shown to correlate with Ti, thus implying that 
axonal density also has influence on Ti (Brex et al., 2000; van Walderveen et al., 
1999). Ti relaxation time measurement therefore appears to be a sensitive but non­
specific technique that can detect a number of pathological processes known to occur 
in MS.
In this study, a degree of intra-subject variability was observed (for all measures, the 
COV was >2.0% and, for patient peak height, the COV was -6%). This variation 
could, in part, be due to biological processes (for instance, due to fluctuation in tissue 
hydration), and in part be methodological in origin. However, the fact that the peak- 
height COV was higher in patients than controls might suggest that the parameter 
was detecting a disease-associated fluctuation in Ti, (possibly secondary to 
inflammatory change). Nonetheless, it should also be noted that a technique which 
relies on a two-point calculation, using two data sets acquired sequentially and not 
simultaneously (as in interleaved sequences), may be prone to short term fluctuations 
in scanner gain (Jackson et al., 2004). With this in mind, future work may need to 
further investigate the stability of quantitative MRI.
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Even with a degree of intra-subject variability, clear differences between patients and 
controls were apparent and abnormality was observed in both NAWM and NAGM. 
However, there was no strong evidence for a serial change and this could reflect one 
of two possibilities (or a combination of both). Firstly, if abnormality in MS NABT 
were due to an irreversible pathology (such as axonal loss) which evolved very 
gradually at an early stage of the disease, a technique with limited reproducibility 
may fail to detect a gradual serial change. (This would be particularly true if a serial 
change was small in comparison to the COV). Secondly, changes in Ti, in early MS, 
may reflect a reversible or fluctuating pathological process, such as inflammation; if 
these changes fluctuated rather than progressively deteriorated, there may be little or 
no net change over time. [Of note, previous studies have revealed evidence for 
inflammatory change within the NAWM in patients with early relapsing-remitting 
MS: Myo-inositol is elevated in white matter (Chard et al., 20026), and there is an 
association between Gd enhancement and changes in white matter volume (Tiberio et 
al., 2005)]. A combination of both possibilities, however, may be the most likely: 
While Ti measurement could, in part, be detecting early non-reversible abnormalities 
(such as axonal loss), variability in the measurement (due to measurement error 
and/or the detection of inflammatory change), might prevent the detection of any 
progressive abnormality.
This study has confirmed that Ti abnormality in NAWM and NAGM is an early 
event in relapsing-remitting MS but there was no conclusive evidence for a net 
change over time. Possible reasons for the latter include 1) that Ti is a non-specific 
measure of MS pathology and 2) that a non-interleaved two point method is 
insufficiently reproducible to detect a subtle underlying change. Further studies of
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CIS or early relapsing-remitting MS patients using alternative Ti calculation 
techniques (for instance those that acquire three or more points, or interleave the data 
sets) may be warranted. However, the potentially non-specific nature of Ti 
abnormality may still limit its’ usefulness as a surrogate endpoint.
Although the measurement of T] relaxation time failed to detect a definite and or 
consistent change over time, it remains possible -  for reasons given above -  that 
increasing pathological abnormalities are genuinely occurring; this possibility is also 
reinforced by studies that have detected progressive grey matter atrophy in the same 
cohort (Chard et al., 2004, Tiberio et al., 2005). As discussed in Chapter 2, MTR has 
been particularly useful in the study of MS and attention was therefore turned to the 
study of the early relapsing-remitting MS cohort using MTR. At the time of 
performing the studies in this thesis it was not known whether grey matter MTR was 
abnormal in early relapsing-remitting MS and whether NAWM and NAGM MTR 
progressively decreased in early disease. These questions are addressed in Chapters 4 
and 5.
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CHAPTER 4
Evidence for grey matter MTR abnormality in minimally disabled early 
relapsing-remitting multiple sclerosis patients
While MTR abnormality has been observed in the normal-appearing white matter 
(NAWM) in clinically isolated syndromes suggestive of MS (Iannucci et al., 2000), 
and in patients with early relapsing-remitting MS, (within three years of symptom 
onset) (Griffin et al., 20026); comparatively little is known about grey matter MTR 
abnormality at such an early stage of the disease.
Normal-appearing grey matter (NAGM) MTR abnormality has been observed in 
relapsing-remitting MS, in patients with disease durations up to 15 years (Ge et al.,
2001), but, in contrast, a study using small regions of interest (ROIs) placed within 
the grey matter of patients with early relapsing-remitting MS (within three years of 
symptom onset) did not detect evidence for grey matter MTR abnormality (Griffin et 
al., 2002b). It is possible, however, that by measuring MTR globally throughout grey 
matter (via histogram analysis), subtle abnormalities may be detected. Of note, two 
recent studies have shown that grey matter and thalamic MTR are abnormal in 
patients with clinically isolated syndromes suggestive of MS, implying that grey 
matter MTR is likely also to be abnormal in early relapsing-remitting MS 
(Traboulsee et al., 2002; Audoin et al., 2004).
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This study builds on the earlier work of Griffin et al. (20026) by imaging a larger 
cohort of non-disabled early relapsing-remitting MS patients and, rather than 
analysing small ROIs, MTR measurements have been achieved using a tissue 
segmentation technique that allows for a global, but tissue specific (i.e. of grey and 
white matter separately) assessment of MTR change in early MS. The aims of the 
study were 1) to establish whether MTR histograms are sensitive to normal 
appearing grey matter change in early relapsing-remitting MS in the absence of 
significant disability and (2) to assess whether grey matter or white matter MTR 
measures were associated with clinical measures of impairment in early relapsing- 
remitting MS.
4.1 Methods
Subjects — MTR and lesion load measures
Thirty eight patients with clinically definite early relapsing-remitting MS (Poser et 
al., 1983; Lublin and Reingold, 1996) (28 female and 10 male; mean age 36.3 years, 
range 24-56 years; disease duration at baseline (time from first symptoms): 1.9 years, 
range 0.5-3.7 years; median expanded disability status (EDSS) (Kurtzke, 1983) score 
1.5, range 0-3) and 35 healthy controls (19 female and 16 male; mean age 38.5 years. 
Range 23-59 years) were studied. Patients were not on disease modifying medication 
when imaged. EDSS scores (Kurtzke, 1983) and MS functional composite (MSFC) 
scores (Fischer et al., 1999) were determined in all patients. The MSFC is a 
composite measure of clinical impairment, encompassing a test of cognition [the 
Paced Auditory Serial Addition Test (PASAT)], a test of upper limb function [the
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Nine Hole Peg Test] and a test of lower limb function [a 25 foot timed walk]. The 
patients were not significantly disabled (by definition EDSS equal or less than 3) but 
they did have a range of milder clinical impairments that were quantified using the 
EDSS and MSFC.
Subjects -  Atrophy measures
A subset of those imaged with the MT sequence also underwent 3D imaging of the 
brain permitting brain volume determination. Thirty seven of the MS patients (28 
female and 9 male, mean age 36.1 years, range 24-56 years; disease durationl.8 
years, range 0.5-3.7 years; median EDSS score 1.5, range 0-3) and 17 of the healthy 
controls (10 female and seven male; mean age 35.9 years. Range 30-54 years) were 
studied with this additional sequence.
The study was approved by the joint ethics committee of the Institute of Neurology 
and the National Hospital for Neurology and Neurosurgery, Queen Square, UK. 
Written informed consent was obtained from all subjects.
MRI acquisition
Imaging was performed on a 1.5 Tesla Signa scanner (General Electric, 
Milwaukee).The 2D dual echo interleaved spin echo (SE) MTI sequence has been 
described previously (Barker et al., 1996) and was acquired in all controls and MS 
subjects. Repetition time (TR) was 1500ms with echo times (TE) of 19/90 ms. 
Images were acquired with a 128x256 matrix over a 24cm field of view (FOV) and 
reconstructed as a 256x256 matrix. Twenty eight contiguous 5mm axial slices 
covering the whole brain were acquired both with and without presaturation. The 
saturating MT pulse was 64ms in duration and 2kHz off water resonance. The power 
of the MT pulse was 14.6pT with a flip angle of 1430° .Saturated and unsaturated
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images were interleaved resulting in inherently registered, saturated and unsaturated 
data sets. MTR was calculated from the short echo images on a pixel by pixel basis 
according to {[M0-MS]/[M0]} x 100 percent units (pu) where Ms and M0 represent the 
signal intensities with and without the saturation pulse respectively. In a subset of 
subjects, a 3D inversion-prepared fast spoiled gradient recall (3D FSPGR) sequence 
[TR 16ms, TE 4.2ms, inversion time 450ms, matrix 256x160, FOV 300x225mm 
(interpolated during reconstruction to a final in-plane resolution of 1.2x1.2mm), 
NEX 1, with 124x1.5mm slices covering the whole brain] was also acquired during 
the same scanning session. The acquisition time was 30 minutes.
Image post processing: MTR and lesion load analysis
Lesions were contoured using Dispimage (Plummer, Dept of Medical Physics and 
Bioengineering, UCL, UK) on the unsaturated proton density weighted images 
according to previously defined criteria (Sailer et al., 1999). Segmentation of the T2 
weighted images into grey matter, white matter and CSF segments was achieved 
using SPM99 (Statistical Parametric Mapping, Wellcome Department of Cognitive 
Neurology, Institute of Neurology, Queen Square, London). (Figures illustrating the 
segmentation methodology can be seen in the Appendix and in Figure 4.2 at the end 
of the results). A whole brain mask (excluding CSF and other non brain parenchyma) 
was generated in SPM99 and then applied to the (inherently registered) MTR map. 
An algorithm, utilizing the grey and white matter probability outputs from SPM99 
was then used to segment the MTR whole brain map into white matter and grey 
matter segments: (Voxels were determined as grey matter or white matter depending 
upon which probability map demonstrated the greatest probability at that location). 
Lesions were excluded from the analysis by setting their pixel value to zero, leaving
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only (NAWM) and (NAGM). Partial volume voxels were minimized with a 10 pu 
threshold and two successive erosions of white matter and a single erosion of the 
grey matter (two erosions of grey matter resulted in only a few GM voxels 
remaining). Normalized NAWM and NAGM histograms were generated with a bin 
width of O.lpu and a smoothing window of +/- 0.3pu. The mean MTR for NAWM 
and NAGM were calculated from these histograms.
Image post processing: Atrophy measures
Brain volume measurements were determined using the 3D FSPGR data which was 
processed in SPM99 to generate probability maps as described above. Brain stem 
and spinal cord were excluded from the analysis by visually determining the slice 
immediately caudal to the cerebellum. Volumes were then estimated using in-house 
software as previously described by Chard et al., (2002a). Lesion masks were 
derived (using lesion segmentations performed manually) and voxels lying within 
these masks were defined as lesional tissue. All other voxels were then defined as 
grey matter (GM), white matter (WM), CSF or other brain parenchyma (eg skull of 
scalp) depending upon which probability map demonstrated the greatest probability 
at that location. The total intracranial volume (TI) was then estimated by adding the 
GM, WM, CSF volumes and lesion volumes. Brain parenchymal fraction (BPF) was 
then calculated as (GM + WM + lesion volume)/ TI. The grey matter fraction (GMF) 
and white matter fraction (W^MF) were also estimated by calculating GM/TI and 
(WM + lesion volume)/TI respectively.
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Validation o f  segmentation technique in the presence offocal white matter lesions
As the presence of lesions may have an effect on SPM99 tissue segmentation, and 
thus differentially affect MS and control subject results, an assessment of the degree 
of lesion associated bias was made. (Further details can be seen in the Appendix). In 
all controls, 60 artificial lesions (uniform cylindrical volumes, each 0.25 ml) were 
placed within white matter, providing a simulated lesion volume of 15ml per subject. 
This corresponded to the average lesion volume observed in the MS subjects. The 
signal intensity of artificial lesions was set at a value that appears to have the most 
marked effect upon SPM99 segmentation (mid way between grey matter and CSF 
signal intensity). The average change in mean white matter MTR and mean grey 
matter MTR was +0.03 pu and -0.09pu respectively. This small effect was 
insufficient to account for any differences subsequently seen between MS patients 
and control subjects (see Appendix for more details).
Statistical Analysis
MTR and atrophy were compared between MS subjects and controls using linear 
modelling (SPSS 11.0). Gender and diagnosis (MS or control) were included as 
fixed factors, with age as a continuous covariate. This approach was prospectively 
defined on the basis of the age and gender imbalances between patients and controls. 
Associations between clinical parameters and MTR were estimated using 
Spearman’s Rank Correlation test.
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4.2 Results
Imaging
Average T2 lesion load in the MS subjects was 14.9ml (mean), 12.4 ml (median), 
range 2.1ml to 47.7ml.
Mean NAWM MTR in MS subjects was 37.9 pu, standard deviation (SD) 0.5 pu 
while in controls, NAWM MTR was 38.3 pu, SD 0.4 pu. Linear modelling revealed a 
significant disease effect on NAWM MTR (p = 0.001) but no significant effect fo r. 
either age or gender (Table 4.1). Mean NAGM MTR in MS subjects was 31.9 pu, SD 
0.6 pu while in controls NAGM MTR was 32.3 pu, SD 0.5 pu. Linear modelling 
revealed a significant disease effect on NAGM MTR (p < 0.001) and also a 
significant effect of gender (p < 0.001), with female subjects having higher grey 
matter MTR than males. No effect of age on NAGM MTR was observed (Table 4.1). 
It should be noted that when artificial lesions were added to the control images and 
comparisons made between patients and controls (using the same linear model) the 
linear model disease effect remained significant for NAGM (p = 0.004) and NAWM 
(p < 0.001) (see Appendix for more details).
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Table 4.1. mean NAWM and NAGM MTR values (and Standard Deviations) in 
patients and controls.
MS Subjects n = 38 Controls n = 35 p value3
NAWM MTR 37.9 pu 38.3 pu p = 0.001
(0.5 pu) (0.4 pu)
NAGM MTR 31.9 pu 32.3 pu p < 0.001
(0.6 pu) (0.5 pu)
a significance of disease effect factor (MS or control) in linear model
T2 lesion load was inversely correlated with NAGM (Spearman’s correlation co­
efficient (r) = -0.56 p < 0.001) and NAWM MTR (r = -0.53, p = 0.001). In subjects 
with MS, NAGM MTR correlated with NAWM MTR (r = 0.43, p = 0.008). In 
controls, only a trend for an association between NAGM MTR and NAWM MTR 
was seen (r = 0.33, p = 0.06).
Volume measures derived from the 124 slice 3D data set (a sub set of the cohort) 
revealed evidence for increased whole brain and WM atrophy in MS subjects. BPF 
was 0.810 (SD 0.026) in MS subjects versus 0.835 (SD 0.28) in controls, linear 
model disease effect: p < 0.001. WMF was 0.263 (SD 0.017) in MS subjects versus 
0.282 (SD 0.012) in controls, linear model disease effect term: p < 0.001. GMF was 
0.547 (SD 0.023) in MS subjects versus 0.552 (SD 0.023) in controls, linear model 
disease effect term: non significant (p = 0.18). BPF correlated with NAGM MTR (r = 
0.69, p < 0.001) but not with NAWM MTR (r = 0.21, p = 0.21). The effect of
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atrophy on NAGM MTR was therefore assessed by including BPF as a covariate in 
the linear model (with gender as a fixed factor). This revealed that the disease effect 
on NAGM MTR remained significant (p = 0.009).
Clinical Status
Median EDSS in MS subjects was 1.5 (range 0-3). EDSS was inversely correlated 
with NAGM MTR (r = -0.45 p = 0.005) (see Figure 4.1) but not with NAWM MTR 
(r = -0.2, p = 0.9). BPF was inversely related to EDSS (r = -0.39, p = 0.02). 
Borderline significance was seen for an association between T2 lesion load and 
EDSS (r = 0.31, p = 0.06). The MSFC score and the three Z scores from which the 
MSFC is derived (Z-arm, Z-cognition and Z-leg) were also determined in this 
cohort16. Borderline evidence for an association was seen between Z-arm and 
NAGM MTR (r = 0.31, p = 0.06) but no other association was seen between the 
MSFC or Z scores and MTR measures. T2 lesion load was inversely correlated with 
the MSFC (r = -0.36, p = 0.03) and also correlated with the Z-leg score (r = 0.44, p = 
0.005). (More positive values correspond to greater disability with the Z-leg score 
yet the converse is true with the MSFC). Borderline evidence was seen for an inverse 
association between disease duration and NAWM MTR (r = -0.29, p = 0.08) but not 
with NAGM MTR.
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Figure 4.1. Correlation between EDSS and NAGM MTR, r = -0.45, p = 0.005.
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Figure 4.2. Images from a patient with MS (top two rows) and healthy control (lower 
two rows). Left column: T2 weighted images. Central column: grey matter segments
of the MTR map (above) subjected to a lOpu threshold and one erosion (below). 
Right column: white matter segments of the MTR map (above) subjected to a lOpu 
threshold and two erosions (below).
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4.3 Discussion
This study detected NAGM and NAWM MTR abnormalities in relapsing-remitting 
MS, in a cohort who have early disease (mean disease duration 1.9 years) and mild 
clinical impairments. Furthermore, clinical impairments in this early relapsing- 
remitting MS cohort were associated with NAGM abnormality but not with changes 
in NAWM.
The ability to detect grey matter abnormality with MTR has previously been 
demonstrated in a cohort with established relapsing-remitting MS (mean disease 
duration 5 years, range 1-15 years, EDSS range 1-6) (Ge et al., 2002) but it has not 
been shown in relapsing-remitting MS patients with minimal disability and early 
disease. Grey matter involvement however appears to be a feature of early relapsing- 
remitting MS and this has been shown in studies using several other MR measures, 
including Ti relaxation, spectroscopic metabolites, and atrophy (Griffin et al., 2002; 
Chard et al., 2002a, 2002b). Also in a recent study of patients with clinically isolated 
syndromes suggestive of MS, a reduction of 0.3 pu NAGM MTR was observed 
(Traboulsee et al., 2002).
Changes within normal-appearing brain tissue in MS have potential to play an 
important role in the development of disability particularly as changes in lesion load 
correlate only modestly with clinical status (Molyneux et al., 2001; Paolillo et al.,
2002). MR methods of assessing change within normal-appearing tissue may 
therefore be of use in clinical trials. This would particularly be true if such measures 
are shown to be good predictors of future impairment or disability, since a key
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requirement of a validated surrogate outcome measure is that it should be associated 
with a clinically relevant outcome (McFarland et al., 2002). An additional valuable 
feature would be that such measures be sensitive to normal appearing tissue 
abnormality early in the course of the disease, prior to the onset of significant 
disability.
Whilst NAGM MTR was associated with clinical impairment using the EDSS, T2 
lesion load was associated with clinical impairment using the MSFC. Potentially 
both lesions and NAGM abnormalities contribute to clinical dysfunction, and 
although they were partly correlated with each other, their effects on clinical function 
may be different. However, before concluding that such outcome measures have 
complementary roles in studies of natural history and treatment monitoring, it would 
be important to study larger cohorts and serial data.
The present study relied upon accurate tissue segmentation and, in particular, that the 
presence of MS lesions did not significantly effect voxel classification. In order to 
quantify this, lesion simulation was performed in controls. The effect noted, 
however, was small and insufficient to account for the MTR changes observed. In 
addition, the segmentations were independently verified by a rater (Waqar Rashid), 
blinded to the clinical details of the subjects, and the segmentations appeared to be 
anatomically valid.
The effect of partial volume voxels at the CSF -  grey matter interface proportionally 
have a greater effect on the mean grey matter MTR as atrophy occurs. In this cohort, 
atrophy has been shown to occur (albeit principally within white matter) and
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therefore it is possible that some of the MTR decrease is partial volume related. As a 
result, every possible attempt has been made to reduce partial volume voxels via the 
use of a CSF-reducing-threshold and erosion of outer voxels. One erosion was used 
in grey matter as further erosions resulted in only very limited amounts of grey 
matter remaining. With these steps, it seems more likely that the NAGM MTR 
abnormality reflects true intrinsic abnormality rather than partial volume effects of 
atrophy. Partial volume voxels at the GM-WM interface and the WM-CSF interface 
may also have an effect on MTR but as erosions where performed at the inner 
surface (as well as the outer) these partial volume voxels will also have been 
minimized.
In further support of NAGM MTR abnormality being secondary to intrinsic tissue 
pathology rather than atrophy per se, BPF was included as a covariate in the 
statistical analysis. Such an analysis is conservative as it is liable not only to 
eliminate MTR differences secondary to partial volume artifact but also to eliminate 
intrinsic MTR differences which are associated with atrophy. Nonetheless, when this 
analysis was performed differences were still observed between patient and control 
NAGM MTR.
The atrophy noted in this cohort appears to be principally secondary to white matter 
volume change although GM volume in the patients was lower (albeit non- 
significantly) than the controls. A previous study (Chard et al., 2002a) did show a 
small but significant degree of GM atrophy in early RRMS and the inability to detect 
it here might result from the fact that the present study had fewer controls.
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A further concern is that juxta cortical lesions and peri-lesional tissue may have been 
erroneously classified as grey matter. However, overt lesions are removed by lesion 
masking and subtle areas of abnormality, (not detected on PD weighted imaging) 
would have MTR values mid-way between grey matter and white matter. Such areas 
therefore would not decrease NAGM MTR.
The statistical analysis used was prospectively designed and used linear modelling to 
account for age and gender imbalances seen between MS and control subjects. 
Where positive disease effects were found, differences between patients and controls 
were verified with the Mann-Whitney U test (which proved to be significant, p < 
0.01) for all such results. Corrections for multiple comparisons have not been 
performed (principally as the number of comparisons was not large) and so some of 
the weaker correlations should be viewed with caution.
What is the pathological basis for the observed normal-appearing brain tissue MTR 
abnormality in early MS? It is known that MTR correlates with axonal and myelin 
density (van Waesberghe et al., 1999), but also, to a certain extent, with 
inflammatory change (Gareau et al., 2000). In NAWM, histopathological findings 
include gliosis, inflammatory infiltrates and axonal loss (Allen and McKeown, 1979; 
Evangelou et al., 2000) with the latter occurring possibly as a result of Wallerian 
degeneration of axons transected in lesions. It is notable that acute axonal transection 
occurs in inflammatory lesions (Trapp et al., 1998), more so at an early stage of the 
disease (Kuhlmann et al., 2002). In grey matter, neuronal and myelin loss has been 
reported in grey matter lesions, which are less inflammatory (Peterson et al., 2001)
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and less MR visible than lesions in white matter (Kidd et al., 1999). Such changes 
might account for the MTR abnormalities seen in this study.
In conclusion, this study demonstrates that MTR is sensitive to NAGM (and 
NAWM) abnormalities in relapsing-remitting MS in a cohort who have early disease 
(mean disease duration 1.9 years) and only mild clinical impairments. The 
correlation of EDSS and grey matter MTR suggests that NAGM MTR abnormality is 
clinically relevant in early relapsing-remitting MS and therefore may have potential 
as a surrogate marker in clinical trials. However, these modest correlations are 
preliminary and so should be confirmed in a larger cohort. In addition, in order to act 
as a surrogate marker, it is necessary to demonstrate that MTR in early MS is 
sensitive to change over time (this is addressed in Chapter 5) and that MTR changes 
correlate with future disability. If such associations are shown, it would imply that 
MTR measures could be a clinically relevant outcome for therapeutic interventions.
I l l
CHAPTER 5 
Increasing normal-appearing grey and white matter MTR abnormality in early 
relapsing-remitting MS
Chapter 4 focussed on the baseline MTR characteristics of this early relapsing- 
remitting MS cohort. In this chapter, serial NAWM and NAGM MTR changes are 
investigated in a subset of patients followed up for two years with yearly scans. The 
study addressed the following questions: (i) Are longitudinal changes occurring in 
NAWM, NAGM or in both regions? (ii) Using back projection methods, when did 
the changes probably start?
5.1 Methods 
Subjects
Twenty three patients with clinically-definite early relapsing-remitting MS (Poser et 
al., 1983; Lublin and Reingold, 1996) were studied. [Note that the 23 patients studied 
here were not identical to those studied in Chapter 3 (although there is a large 
overlap) -  the patients include here had MTR data sets available for at least two of 
the three yearly time points]. The demographics of the patients were as follows: (19 
female and four male; mean age: 37 years, range: 27-55 years; disease duration at 
baseline (time from first clinical event): 1.9 years, range: 0.5-3.7 years; Median 
EDSS score: 1.0, range: 0-3.0). Nineteen healthy controls were also imaged: (10 
female and nine male; mean age: 34 years, range: 27-52 years). All subjects were 
imaged at baseline with 22 MS patients and 18 controls imaged one year later (range:
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11-15 months) and 21 MS patients and 10 controls imaged two years later (range: 
23-28 months). Patients were not on disease modifying medication at baseline; 
however, seven of the 23 MS patients commenced treatment with Beta-interferon 
(IFNB) during the study period; all of whom completed the two year follow up. The 
patients had not been administered steroids within a month prior to imaging. EDSS 
scores and MS function composite (MSFC) scores (Fischer et al., 1999) were 
determined at each visit. The study was approved by the joint ethics committee for 
the Institute of Neurology and the National Hospital for Neurology and 
Neurosurgery, Queen Square, London, UK. Written informed consent was obtained 
from all subjects.
Magnetic Resonance Imaging
Imaging was performed on a 1.5 Tesla Signa (General Electric, Milwaukee, USA). 
The 2D interleaved dual spin echo magnetisation transfer imaging sequence has been 
described previously (Barker et al., 1996) and was acquired in controls and MS 
patients at all time points. The imaging parameters have been given previously 
(Chapter 4). As mentioned, saturated and unsaturated images were interleaved 
resulting in inherently registered saturated and unsaturated data sets. MTR, in percent 
units (pu) was calculated from the short echo images on a pixel by pixel basis 
according to {[M0-MS]/[M0]} x 100 where Ms and M0 represent the signal intensities 
with and without the saturation pulse respectively. The acquisition time was 20 
minutes.
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Image Post Processing.
Lesions were outlined on the unsaturated short echo images according to previously 
defined criteria (Sailer et al., 1999), using a semi-automated contouring method 
implemented within the Dispimage program (Plummer, 1992). Segmentation of the 
MTR map into NAWM and NAGM segments was achieved using an identical 
technique to that described in Chapter 4.
Volume measures were also determined using the SPM99 probability outputs (from 
the MTR data sets). These volume measures were obtained in order that a measure of 
atrophy could be included as a covariate in the statistical analysis. Brain stem and 
spinal cord were excluded from the analysis by visually determining the slice 
immediately caudal to the cerebellum and volumes were then determined using in- 
house software as described in Chapter 4.
Statistical Analysis
Changes in MTR over time were modelled using hierarchical regression (Goldstein, 
1995) with random subject-specific intercept and common slope on time, using a 
time scale with origin at study baseline; patient indicator and patient x time 
interaction terms were used to assess patient vs. control differences. The same model 
was used to investigate changes in atrophy measures over time. There was no 
evidence that a random slopes model gave a better fit. Potential confounding by age, 
gender and BPF was examined by adding these terms and interactions into the 
regression. For NAWM MTR, BPF and its interaction with patient indicator 
contributed to the model, but terms in age and gender were omitted from the model 
as there was no evidence of confounding by these. For NAGM, BPF and its
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interaction with patient indicator, gender, gender x BPF interaction were included, 
and age omitted as there was no evidence that it confounded. Non-parametric bias- 
corrected bootstrap estimates (Carpenter and Bithall, 2000) were derived (1000 
replicates) to confirm parametric results where normality could not confidently be 
assumed; where bootstrap and parametric results differed materially the former are 
reported in the text.
Reported baseline patient vs. control differences in MTR are the covariate adjusted 
estimates given by these longitudinal models, and therefore differ slightly from the 
crude cross-sectional difference. The former estimates are preferred not only 
because of adjustment for confounding, but because all the data points are used, thus 
reducing the error of estimates from just one time point.
The statistical comparison between the rates of change in NAWM MTR and NAGM 
MTR was carried out in patients only by testing for a difference in the coefficients on 
time from baseline in two models: for NAWM MTR, only time was entered as 
predictor (other terms did not contribute and were omitted). For NAGM MTR, 
gender, BPF and their interaction were also entered. Quadratic terms in time were 
used to test for non-linearity, on both baseline and onset origin time scales.
To estimate by back extrapolation when patient MTR diverged from normal control 
values, the latter were estimated as the mean across the time points in controls, 
reflecting an a priori assumption of no change in controls, and the regression, in 
patients only, used the onset origin time scale. No covariates were entered for 
NAWM or NAGM MTR; BPF was omitted in order to estimate the rate of change
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due to the whole disease process, rather than the MTR component only, which is 
estimated in the BPF adjusted models. Gender was omitted to simplify the 
comparison and presentation in Figures 5.1 and 5.2. To check consequences of this 
simplification, the GM back projection was also calculated with gender and gender x 
time interaction, using females as comparator to give a time to normality in females 
only. Non-parametric bias-corrected bootstrap (1000 replicates) was used to derive 
confidence intervals for the time at which abnormality begins.
Associations between atrophy and MTR variables were examined with random 
intercept regression models using MTR outcome and atrophy and time predictors. 
Longitudinal changes in EDSS and lesion load were examined with Wilcoxon signed 
rank tests, and in the MSFC with a paired t-test. Cross-sectional associations 
between MR parameters, and between these and clinical variables, were assessed 
using Spearman rank correlation.
5.2 Results
Baseline M RI Findings
Mean baseline T2 lesion load was 16.6ml (median: 13.3ml, range: 2.1-47.7ml). The 
mean MTR values from NAWM and NAGM are given in Table 5.1. Compared to 
controls, the patients’ mean MTR was significantly lower in both NAWM (mean 
difference -0.6pu; 95% confidence interval (Cl) -0.3pu, -0.9pu; p < 0.001) and 
NAGM (mean difference -0.5pu; 95% Cl -O.lpu, -0.8pu; p = 0.004).
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Table 5.1: Baseline values for patient and control NAWM and NAGM MTR.
Patients 
n = 23
Controls 
n=  19
p value*
Mean (SD) Range Mean (SD) Range
NAWM
MTR
37.8pu
(0.5pu)
36.3-38.7pu 38.3pu
(0.4pu)
37.4-39. lpu < 0.001
NAGM
MTR
32.0pu
(0.7pu)
30.7-33.5pu 32.4pu
(0.5pu)
31.1-33.0pu 0.004
p values derived from covariate adjusted estimates of baseline patient-control 
difference in longitudinal model. SD = standard deviation, pu = percent units.
Longitudinal Changes
Clinical follow up at two years
Clinical comparisons between baseline and the two year time point revealed no 
significant change in MSFC scores (p = 0.76). Median EDSS increased from 1.0 
(range 0 to 3.0) to 1.5 (range 0 to 4.0) (p = 0.02). All but one patient had an EDSS of 
less than 4.0 at two years. Mean annual relapse rates prior to, and following study 
entry were 1.5 and 0.7 respectively. The mean time between the first and second 
attack (prior to study entry) was 9 months; (median 8 months).
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Serial T2 lesion load measurement at baseline and at two years 
Significant changes in T2 lesion load were not seen during follow up. In the 21 
patients followed up for two years, the mean T2 lesion load at baseline was 14.6ml 
compared to 15.0ml at two years (p = 0.82). Over the two years, T2 lesion load 
increased in 11 patients and decreased in 10. Seven of the 21 MS subjects followed 
up at two years were taking IFNB (having started since baseline scan) and five of 
these had reductions in T2 lesion load. However, when those on IFNB were 
excluded, there was still no significant increase in T2 lesion load over time.
Regression analysis o f serial NA WM MTR data (Figure 5.1)
In patient NAWM, MTR was progressively declining at an estimated annual rate of 
-O.lOpu (p = 0.001; 95% Cl: -0.04, -0.15). In controls, the annual rate of WM MTR 
change was not statistically significant: +0.04pu (p = 0.20; 95% Cl: -0.02, +0.10). 
The patient-minus-control difference in the annual rate of MTR change was also 
statistically significant: -0.14pu (p = 0.001; 95% Cl: -0.05, -0.22).
Regression analysis o f serial NAGM MTR data (Figure 5.2)
In patient NAGM, MTR was progressively declining at an annual rate of -0.18pu (p 
< 0.001; 95% Cl: -0.11, -0.24). In controls, the annual rate of GM MTR change was 
not statistically significant: +0.01pu (p = 0.74; 95% Cl: -0.06, +0.09). There was a 
statistically significant patient-minus-control difference in the annual rate of MTR 
change: -0.19pu (p < 0.001; 95% Cl: -0.09, -0.28).
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Comparison o f NA WM and NAGM rates o f change in MS patients 
The rate of change in NAGM was significantly greater than the rate of change in 
NAWM (p = 0.004). No significant correlations were found between relapse rate 
and MTR change in NAGM or NAWM; nor between changes in MTR and changes 
in EDSS or MSFC. Furthermore, no significant correlations were seen between the 
cognitive component of the MSFC (the Z-cog score) and MTR change. There was 
also no correlation found between changes in NAGM or NAWM MTR and either 
baseline T2 lesion volume or change in T2 lesion volume. Finally there was no 
significant difference between the rates of NAWM and NAGM MTR change in those 
who started IFNB and those who did not.
Backwards extrapolation o f rates o f change
There was no evidence of non-linearity in NAWM or NAGM MTR change over the 
time range of the data, either on the baseline or onset origin time scales. Assuming 
that the gradient of change in controls was zero, and in patients was linear at all 
times, NAWM MTR abnormality began 2.9 years before clinical onset (95% Cl: 0.7 
to 11.1 years before, p = 0.015) (see Figure 5.1), and NAGM MTR abnormality 
began 0.4 years after clinical onset (95% Cl: 1.0 year before to 1.2 years after, p = 
0.6) (See Figure 5.2). [Inclusion of gender in the NAGM model revealed that NAGM 
MTR abnormality began 0.1 years after clinical onset (95% Cl: to 1.4 years before to 
1.4 years after, p = 0.8)]. The difference between the extrapolated times of onset for 
the two tissues was statistically significant: NAWM abnormality preceded NAGM 
abnormality by 3.3 years (95% Cl: 1.5 to 11.3 years, p < 0.001).
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Tissue volume measures (Table 5.2)
Tissue volume measures were calculated in order that BPF could be included as a 
potential confounder in the longitudinal analysis. NAGM MTR in patients was 
positively correlated (independently of time) with BPF (p < 0.001) but not GMF (p = 
0.1 bootstrap) or WMF (p = 0.89). NAWM MTR did not correlate (independently of 
time) with BPF (p = 0.45), GMF (p = 0.98) or WMF (p = 0.40). WMF was lower at 
baseline in patients than controls (p = 0.01), but there was no evidence of decline in 
either patients or controls. There was weak evidence that GMF at baseline was 
higher in patients than controls (p = 0.04, bootstrap), and there was some evidence of 
decline in GMF in both patients (p = 0.01, bootstrap) and controls (p = 0.02 
bootstrap), but not a statistically significant difference in rate (p = 0.7, bootstrap). 
BPF showed a significant decline in patients (p < 0.001) (with no statistical evidence 
of non-linearity), but not in controls (p = 0.24), though there was no statistically 
significant difference between patients and controls at baseline or in rate of decline.
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Table 5.2: Tissue volumes: mean BPF, GMF and WMF (and standard deviations) in 
patients and controls.
Baseline 
Patients n = 23 
Controls n =19
12 months 
Patients n = 22 
Controls n =18
24 months 
Patients n = 21 
Controls n =10
Patients BPF .848 .841 .840
(.022) (.022) (.021)
GMF .495 .488 .487
(.026) (.022) (.024)
WMF .353 .353 .353
(.015) (.014) (.017)
Controls BPF .849 .850 .849
(.016) (.020) (.017)
GMF .483 .476 .475
(.031) (.017) (.012)
WMF .366 .374 .374
(.025) (.014) (.013)
BPF = brain parenchymal fraction, GMF = grey matter fraction, WMF = white 
matter fraction
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Figure 5.1. NAWM MTR in MS patients plotted against time from clinical 
onset. Thick red dashed line: mean control NAWM MTR value. Red shaded 
area: 95% confidence intervals for the control mean. Thin dashed red lines: 
control mean +/- two standard deviations. The line of best fit from the 
hierarchical regression is in solid black.
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Figure 5.2. NAGM MTR in MS patients plotted against time from clinical onset. 
Thick red dashed line: mean control NAGM MTR value. Red shaded area: 95% 
confidence intervals for the control mean. Thin dashed red lines: control mean 
+/- two standard deviations. The line of best fit from the hierarchical regression 
is in solid black.
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5.3 Discussion
MTR findings in NA WM and NAGM
This study extends the observation that NAWM and NAGM MTR are both abnormal 
in clinically early RRMS (Chapter 4), by showing that the MTR abnormalities in 
both regions progressively increase over two years of follow-up. In addition, 
backward extrapolation of the rates of change -  assuming linearity -  suggests that 
NAWM MTR abnormality is present prior to the onset of symptoms and precedes 
NAGM MTR abnormality.
As previously mentioned, MTR relies upon the use of an off-water-resonance 
radioffequency pulse capable of selectively saturating the macromolecular 
magnetisation. As a result, MR visible free water is saturated via exchange with this 
macromolecular pool and MTR values represent the percent reduction in signal 
intensity observed. A fall in a tissue’s macromolecular content will result in a lower 
MTR and, consistent with this, MTR is associated with demyelination and a 
reduction in axonal density (Mottershead et al., 2003; van Waesberghe et al., 1999). 
However, small changes in MTR may also be due to inflammation (Gareau et al., 
2000).
The subjects in this study had minimal or no disability at entry (although they did 
have a range of mild clinical impairments). Furthermore, as a group, they did not 
accumulate major disability or enter the secondary progressive phase during follow- 
up, (only one patient reached EDSS 4.0 by two years). Despite this, increasing MTR 
abnormalities were apparent in both NAWM and NAGM. An earlier study showed
124
that normal-appearing brain tissue MTR declines over one year following a clinically 
isolated syndrome suggestive of MS (Filippi et al., 2000a) while an association 
between NAWM MTR and disease duration has also been observed (Laule et al., 
2003). Taken together with the present findings, this suggests that increasing and 
clinically silent pathological abnormalities are developing in normal appearing 
tissues early in the course of RRMS. Longer term follow-up is now needed to 
determine whether or not these changes are associated with later clinical worsening.
The significantly greater rate of change in NAGM compared with NAWM suggests 
either that the nature of the pathological changes within NAGM and NAWM differ 
(and hence have a different effect on MTR), or that the same pathological process is 
occurring more rapidly in NAGM at this stage of the disease. Based on known 
pathological findings (Allen and McKeown, 1979; Allen et al., 2001; Evangelou et 
al., 2000; Kidd et al., 1999; Peterson et al., 2001), the former explanation seems 
more likely. It is unlikely that atrophy affected the relative rates of NAGM and 
NAWM change because the analyses were performed using BPF as a covariate.
The prediction that NAWM abnormality predated symptom onset -  possibly by 
several years -  is based on an assumption that the rate of change prior to entry was 
the same as that observed during the study. If NAWM MTR abnormality had begun 
at the time of the first clinical attack, a substantially steeper decline during the two 
years between clinical onset and study entry would have had to occur. Although, 
there was no evidence of non-linearity over the study period, (giving some 
plausibility to the assumptions made by linear backward extrapolation), the
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extrapolations relied upon data from three time points only, and should be viewed 
with some caution. It is possible that early changes in NAWM and NAGM are non­
linear, and thus have a different dynamic to that suggested by the current data.
Pathological basis o f MTR findings
What could be the pathological basis for the MTR changes seen in this study? 
Studies of the macroscopically normal white matter in MS have revealed evidence 
for astrogliosis (Allen and McKeown, 1979), microglial activation (Allen et al.,
2001) and axonal loss (Evangelou et al., 2000). Patchy demyelination and 
perivascular inflammation may also occur (Allen et al., 1979). Several of these 
processes could result in subtle MTR abnormalities. The progressive NAWM change 
observed is perhaps more likely to be due to the ongoing loss of myelin and axons 
rather than to inflammation, (which would be more likely to fluctuate than progress). 
In grey matter, the accumulation of cortical lesions, which are almost never seen on 
MRI (but are associated with axonal loss and demyelination) (Kidd et al., 1999; 
Peterson et al., 2001), might progressively decrease MTR.
Methodological issues
Progressive brain volume loss could potentially have contributed to the reduction in 
MTR observed, particularly as it is associated with a relative increase in the number 
of partial volume voxels at the CSF/brain tissue interface. Of note, a study of patients 
from the same cohort, using volumetric imaging, reported both grey and white matter 
atrophy; with a progressive decline in grey matter (but not white matter) tissue 
volume during the course of the study (Chard et al., 2004). Rigorous efforts have
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therefore been made to minimize partial volume effects using (i) a CSF minimizing 
threshold, and (ii) erosions of inner and outer voxels. Also, NAGM and NAWM 
MTR changes were analyzed after including BPF as a covariate in the regression 
model. Such an analysis is highly conservative as it will not only minimize MTR 
differences due to partial volume artifact but will also reduce true intrinsic MTR 
differences that are directly associated with atrophy. Brain volume loss per se is 
therefore unlikely to account for the progressive changes observed in MTR
The presence of white matter lesions could theoretically have altered the way in 
which the segmentation software classified voxels, leading to a systematic difference 
between patient and control segmentation. However, this has previously been 
investigated as laid out earlier in this thesis and the small changes caused by lesion 
simulation were not sufficient to account for the NAGM and NAWM MTR changes 
seen in patients with early RRMS (Chapter 4). However, the small effect of lesions 
on tissue segmentation could have contributed to the marginally larger GMF seen in 
the present patient cohort in comparison to controls (Chard et al., 2002c), this being 
an otherwise unexpected finding. Of note, T2 lesion load did not significantly change 
during follow-up and so segmentation bias could not account for the changes seen in 
the normal appearing tissues.
The healthy control data remained stable over the two years of follow-up with a rate 
of change not significantly different from zero. Although there were fewer controls 
than MS subjects, the patient-minus-control difference in the annual rates was 
significant in both tissues, suggesting that the size of the control cohort was
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sufficient for comparison with patients. The number of patients was also not high, 
and as some were treated with IFNB, this potentially might have affected MTR. 
However, no difference in the rate of MTR change was observed when treated and 
untreated patients were compared and a previous study in secondary progressive MS 
reported no treatment related modification of whole brain MTR (Inglese et al., 2003). 
Furthermore, the patient cohort appears representative of early relapsing-remitting 
MS in terms of their relapse rate (IFNB MS Study Group, 1993), EDSS and gender 
distribution.
Conclusions
This study has revealed increasing abnormalities in NAGM and NAWM MTR at an 
early stage of relapsing-remitting MS (mean disease duration 1.9 years). The NAWM 
abnormality may begin before clinical onset of the disease and may precede change 
in NAGM. However, the sample size was relatively small and confirmation of these 
findings is needed. Nevertheless, the findings are potentially important as they 
suggest the occurrence of a diffuse and progressive pathological process early in the 
course of relapsing-remitting MS. Long term follow up is now required to investigate 
the prognostic significance of these changes.
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CHAPTER 6 
Emergence of thalamic MTR abnormality in early relapsing-remitting MS
In Chapters 4 and 5, evidence was presented suggesting that NAGM MTR 
abnormality is clinically relevant (it correlates with the EDSS) and that increasing 
MTR abnormalities are developing in the NAGM and NAWM early in the course of 
relapsing-remitting MS. Focus will now shift to the study of the thalamus, 
particularly as the thalamus (as with the study of grey matter) may give useful insight 
into neuronal abnormality in early MS.
Axonal damage in multiple sclerosis (MS) has been investigated extensively in 
recent years, (Ferguson et al., 1997; Trapp et al., 1998; Kuhlmann et al., 2002) 
particularly as it may be a key factor in the development of permanent disability 
(Bjartmar et al., 2000). A number of recent studies have investigated the thalamus, 
(Cifelli et al., 2002; Wylezinska et al., 2003; Inglese et al., 2004) principally because 
it contains a number of deep grey matter nuclei and extensive fibre tract connections 
including ascending and cortical-striatal pathways. However, while imaging of the 
thalamus in MS may provide useful insight into neuronal abnormality, it also 
contains a significant amount of myelin, (Ohye and Armstrong, 1990) raising the 
possibility that thalamic abnormality may not be entirely neuronal in origin.
One recent study, in secondary progressive MS, using both histopathological and MR 
techniques, (Cifelli et al., 2002) reported a 17% reduction in thalamic volume, 
reduced thalamic N-Acetyl aspartate (NAA) concentrations, and a reduction in 
neuronal density, consistent with a 30% reduction in thalamic neuronal number.
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Furthermore, in patients with established relapsing-remitting MS, (Wylezinska et al., 
2003) (mean disease duration: 7.7 years, expanded disability status scale (EDSS) 
range: 2.0-6.0), a significant reduction in thalamic volume and NAA concentrations 
were also detected.
Currently, it remains unclear how early thalamic abnormality is seen in the clinical 
course of MS. This study used the magnetization transfer ratio (MTR) to ask whether 
thalamic intrinsic abnormality occurs in our early relapsing-remitting MS cohort.
6.1 Methods
Patients with MS and Control Subjects.
Twenty three patients with early clinically-definite relapsing-remitting MS entered 
the study (Poser et al., 1983; Lublin and Reingold, 1996), (these were the same 
patients studied in Chapter 5). Their demographics were as follows: (19 female, four 
male, mean age 37 years, range 27-55 years, median disease duration at baseline 
(time from first clinical event) 1.9 years, mean 1.9 years, range 0.5-3.7 years; median 
EDSS score: 1.0, range 0-3.0.). Nineteen healthy controls were also imaged at 
baseline: (10 female, 9 male, mean age 34 years, range 27-52 years) were imaged at 
baseline. At year one, 22 MS patients and 18 controls were followed-up; (mean 
follow up times were 380 days for patients and 386 days for controls). At year two, 
22 patients and 14 controls completed follow-up; (mean follow up times were 752 
days and 760 days respectively). (One patient missed one-year follow-up, whereas a 
second missed two year follow-up, but serial data was available on all 23). Prior to 
study entry, patients had not been on MS disease modifying medication (such as Beta 
interferon (IFNB) or Glatiramer Acetate) although seven began IFNB between
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baseline and the one year time point. Patients had not received steroids within the 
month prior to any of the imaging sessions. The EDSS, (Kurtzke, 1983) and MS 
Functional Composite Score (MSFC), (Fischer et al., 1999) were determined in 
patients at baseline and at the two year time point. The study was approved by the 
joint ethics committee for the Institute of Neurology and the National Hospital for 
Neurology and Neurosurgery, Queen Square, London, UK. Written informed consent 
was obtained from all study participants.
Magnetic Resonance Imaging
Imaging was performed on a 1.5 Tesla Signa (General Electric, Milwaukee, WI, 
USA). In MS patients and controls, a 2D interleaved dual-echo spin-echo 
magnetization transfer imaging (MTI) sequence and a 2D spin echo Ti weighted 
sequence were acquired at all three time points. The MTI sequence has been 
described previously, (Barker et al., 1996) and the acquisition parameters were given 
in Chapter 4. MTR maps, in percent units (pu) were calculated from the short echo 
images on a pixel by pixel basis according to: {[M0-MS]/[M0]} x 100 where Ms and 
M0 represent the signal intensities with and without the saturation pulse respectively. 
The acquisition parameters for the Ti weighted sequence were: TR 540ms, TE 20ms, 
matrix 256x256, 28 contiguous 5mm slices covering the whole brain.
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Image Analysis
Lesions were outlined on the unsaturated proton density weighted images according 
to previously defined criteria, (Sailer et al., 1999) using a semi-automated local 
thresholding technique available within the Dispimage package (Plummer et al., 
1992). A rater (GRD), blinded to the subject identity and image time point, placed a 
standard cylindrical region of interest (ROI) (volume 945 mm3) on to the MTR map 
such that the ROIs lay entirely within the left and right thalami. (Figure 6.1). 
Thalamic regions of interest were positioned, at each time point, with reference to the 
T2 weighted unsaturated image, taking care to avoid lesions and CSF-containing 
partial-volume voxels. In order to assess whether patients had thalamic lesions, a 
rater experienced in lesion marking (GRD) examined the patient’s T2 weighted 
imaging at all time points, (inspecting all slices on which the thalamus was seen). 
The thalamic ROI was always carefully positioned to include only normal-appearing 
thalamic tissue MTR values from the left and right thalamus were averaged and the 
mean thalamic MTR was used in the subsequent statistical analysis. (An average 
was taken to limit the number of statistical comparisons).
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Figure 6.1. Regions of interest placed onto the MTR map within each thalamus 
(below) with reference to the T2 weighted image (above).
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Statistical Analysis
For the comparison between patients and controls, values of MTR over the three time 
points were modelled using random intercepts regression, (Goldstein et al., 1995) 
with random subject-specific intercepts and common linear slope on time from study 
baseline. MS indicator and MS x time interaction terms were used to estimate patient 
vs. control differences. Potential confounding by age and gender was examined by 
adding these terms as covariates, but age was omitted since it did not contribute nor 
materially affect parameter estimates. The longitudinal model was also used to 
estimate baseline, year-one and year-two cross-sectional patient vs. control 
differences. To investigate the effects of treatment, a similar random intercepts 
model was used in patients-only such that the model included a IFNB indicator term 
and a IFNB indicator x time interaction term to compare the effect of treatment in 
patients; neither age nor gender contributed to patient-only models, and both were 
omitted. To investigate (in patients only) the univariate associations between MTR 
(and MTR change) and both, lesion volume, and clinical disability, Spearman’s 
correlation was used. To investigate whether time modified the association between 
MTR and baseline lesion volume, a random intercepts regression using the following 
terms was used: a MTR response variable on baseline lesion volume term, a time 
indicator term and a lesion volume x time indicator interaction term. A similar 
interaction model was used to investigate whether the association between MTR and 
clinical variables differed between baseline and year two. Changes in EDSS and in 
lesion loads were examined with a Wilcoxon sign rank text, and paired tests were 
used for changes in MSFC and for the timed walk component z score. [In order to 
limit the number of statistical comparisons, an a-priori decision was taken not to 
analyze the PASAT and upper-limb z-scores separately, particularly as both tests are
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prone to practice effects. (Cohen et al., 2001)] Statistical significance was taken as p 
< 0.05. Analyzes were carried out in Stata 8.2 [StataCorp. 2003. Stata Statistical 
Software: Release 8.2. College Station, TX: Stata Corp].
6.2 Results
Clinical Status and Lesion Volume Changes
Over the two year study, the median EDSS increased from 1.0 (range 0-3.0) to 1.75 
(range 0-4.0), p = 0.008; (only one patient had an EDSS score of 4.0 at two years). 
MSFC scores did not change during follow-up (mean MSFC scores at baseline and 
year two were 0.000 and -0.063 respectively, p = 0.72), though there was borderline 
evidence of deteriorating timed walk (z scores were 0.000 and 0.817 respectively, p 
= 0.064). [Mean baseline z scores and the baseline MSFC are always zero as an 
individual’s score is expressed as the number of standard deviations from the 
baseline group mean. It should also be noted that the more positive the z leg score, 
the greater the disability, while the converse is true for the MSFC]. Mean annual 
relapse rate prior to study entry was 1.5, falling to 0.7 during the course of the study.
Median T2 lesion volume at baseline (determined from the proton-density weighted 
MTI images) was 13.3ml [mean: 16.6ml, range: 2.1ml to 47.7ml]. In the 22 patients 
followed up for two years, median lesion volume at baseline was 12.7ml and 12.0ml 
at two years (p = 0.86). Three patients had thalamic lesions noted on T2 weighted 
imaging (two with two lesions each and one with a single lesion). These patients had 
EDSS scores (at two-years) of 2.5, 3.0 and 2.0 respectively, with all three EDSS 
scores being greater than the median. Median Ti lesion volume at baseline was 
0.81ml and 0.74ml at two years (p = 0.53).
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MTR Findings in the Thalamus
Mean MTR values at baseline, year one and year two are given in Table 6.1. [There 
was no statistical difference observed between the left and right thalami (p = 0.6, 
paired samples T-test for patients and controls combined)]. There was no significant 
cross-sectional difference between patients and controls estimated from the 
longitudinal model at baseline. However, during the course of the study a difference 
between patients and controls emerged and at two years the estimated difference 
(adjusted for gender) was -0.6pu, p = 0.005, 95 % confidence intervals (Cl): -l.Opu, - 
0.17pu. Although the estimated rate of change in patients was significant (-0.33 
pu/year, p < 0.001) while that in controls was not (-0.13 pu/year, p = 0.174), the 
difference did not reach statistical significance (-0.20 pu/year p = 0.117). When 
patients treated with Beta-interferon were compared with untreated patients, there 
was no evidence of difference in the change of thalamic MTR during the study (-0.26 
pu/year versus -0.36 pu/year respectively, p = 0.515), nor of an estimated difference 
at two years (p = 0.509). When the changes over time in the treated and untreated 
groups were separately analyzed, both were significant: -0.26 pu/year, p = 0.048 and 
-0.36 pu/year, p < 0.001 respectively.
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Table 6.1. Mean MTR values from the thalamus in MS patients and controls.
N
(patients/controls)
Mean MTR (std dev) 
MS Patients Controls
p value: from
longitudinal
model3
Baseline 23/19 37.2pu
(0.6pu)
37.3pu
(0.5pu)
0.374
One year 22/18 37.2pu
(0.8pu)
37.4pu
(0.6pu)
0.018
Two years 22/14 36.5pu
(0.6pu)
37.0pu
(0.9pu)
0.005
aAdjusted for gender, with no evidence of confounding by age.
Relationship between Baseline Lesion Volume and Thalamic MTR
At baseline, there was no significant correlation seen between lesion volume and 
thalamic MTR, (Spearman’s rank correlation coefficient (rs) = -0.06, p = 0.79). 
However, at year one, a significant inverse correlation between baseline lesion 
volume and year one thalamic MTR emerged rs = -0.49, p = 0.02. At year two, the 
correlation between baseline lesion volume and thalamic MTR at that time point was 
of borderline significance only rs = -0.39, p = 0.08. See Figure 6.2. The association 
at year one is significantly different from that at baseline (p = 0.005) but not from 
that at year two (p = 0.185)
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For Ti baseline lesion volume, the Spearman’s correlations with MTR at baseline, 
year one and year two were 0.00 (p = 0.99), -0.56 (p = 0.007) and -0.15 (p = 0.500) 
respectively. The association at year one is significantly different from that at 
baseline (p = 0.003), but not from that at year two (p = 0.182).
Relationship between Disability and Thalamic MTR
Patient-specific mean EDSS, averaged over time points, was negatively correlated 
with patient mean MTR, rs = -0.47, p = 0.023, and there was no evidence that the 
association differed between baseline and year two (p = 0.276). There was no 
evidence that the rate of change of MTR was associated with EDSS at year two (rs = 
-0.07, p = 0.754). There was a borderline significant positive association between 
patient mean MSFC and mean MTR (rs = 0.40, p = 0.068), and a stronger (and 
negative) association with the walk component (rs = -0.50, p = 0.018). For neither 
MSFC nor the walk component was there evidence of a different association at 
baseline and year two, or of an association between year two values and rate of 
change of MTR.
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Figure 6.2: No correlation is seen between baseline lesion volume and baseline 
MTR. However an inverse correlation emerges between baseline lesion volume and 
thalamus MTR at year one with borderline significance for an inverse correlation at 
year two.
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6.3 Discussion
In this study, thalamic abnormality developed within five years of the first clinical 
event in relapsing-remitting MS, at a stage when most patients had only mild clinical 
impairment. A modest relationship was also seen between lesion volume at study 
entry and subsequent values of thalamic MTR.
Although neuropathological findings in MS include cortical grey matter abnormality 
(Kidd et al., 1999; Peterson et al., 2001; Lumsden, 1970; Brownell and Hughes, 
1962), and MRI has revealed evidence for grey matter atrophy early in the clinical 
course of the disease (De Stefano et al., 2003; Chard et al., 2002), comparatively few 
studies have investigated the thalamus in isolation. Recent studies have revealed 
thalamic atrophy and reduced thalamic NAA concentrations in patients with 
established secondary progressive, (Cifelli et al., 2002), and relapsing remitting MS 
(Wylezinska et al., 2003; Inglese et al., 2004). While an earlier study of relapsing- 
remitting and secondary progressive patients did not find evidence for abnormality in 
the thalamus or basal ganglia when measuring mean diffusivity and MTR (Filippi et 
al., 2001), an increase in the thalamic apparent diffusion coefficient (ADC) has been 
reported in a primary progressive cohort (Schmierer et al., 20046), and in a 
combined relapsing-remitting and secondary progressive study (Fabiano et al., 
2003). A diffusion imaging study has also reported an increase in thalamic fractional 
anisotropy, possibly reflecting a loss of external connectivity (thereby making the 
internal connectivity within the thalamus more apparent) (Ciccarelli et al., 2001). 
Although most of these studies do provide evidence for thalamic abnormality in 
patients with well established MS, the present data additionally suggests that such 
abnormality begins during an early phase of the disease. A recently published study
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(Audoin et al., 2004), appears to confirm this, in that thalamic MTR abnormality was 
detected (using voxel-based morphometry) in patients with clinically isolated 
syndromes suggestive of MS.
As an MR measure, the MTR is sensitive to changes in the macro-molecular content 
of tissue and is reduced by a number of pathological processes, including 
demyelination, axonal loss, and inflammation (van Waesberghe et al., 1999; 
Mottershead et al., 2003; Gareau et al., 2000; Schmierer et al., 2004a; Stanisz et al., 
2004a). Neuro-pathological findings within the thalamus in MS include axonal loss 
and therefore reductions in neuronal number may be one possible explanation for the 
reductions in MTR seen in this study. However, the thalamus also contains a 
significant amount of myelin (Ohye and Armstrong, 1990), and therefore it is 
possible that demyelination may also result in the MTR abnormality observed. 
Although the changes can not be attributable to accrual of MRI visible thalamic 
lesions, (particularly as lesions involving the thalamus were seen in only three 
patients and regions of interest were positioned to lie entirely within normal- 
appearing tissue), small thalamic lesions (not detected on MRI) could theoretically 
also reduce the MTR. On MRI, cortical grey matter lesions are largely invisible 
(Kidd et al., 1999), and this raises the possibility that thalamic lesions are also not 
always seen.
An association was seen between lesion volume at baseline and subsequent values of 
thalamic MTR but a significant correlation was not seen between baseline lesion 
volume and baseline MTR. The emergence of a correlation at year-one raises the 
possibility that early lesion pathology leads to later thalamic abnormality. Neuro-
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pathological findings in MS include the transection of axons in active lesions 
(Ferguson et al., 1997; Trapp et al., 1998; Kuhlmann et al., 2002), a process which 
could, in turn, lead to the antegrade or retrograde degeneration of axons running 
within the thalamus. However, alternative interpretations also need to be considered, 
particularly as a causal relationship between lesion volume and subsequent thalamic 
change has not been proven. A primary abnormality of normal appearing white 
matter, for instance, might lead separately to focal lesion genesis and thalamic 
abnormality, particularly as the thalamus also contains myelin. An additional 
interesting question concerns the specific location of the thalamic abnormality. 
However, the present technique could not adequately distinguish between thalamic 
nuclei and, therefore, further studies are required to address this issue.
Clinical follow-up revealed that the patients did not develop marked disability during 
the course of the study; none entered the secondary progressive phase and all 
remained ambulatory throughout the study period. It therefore appears that thalamic 
abnormality in MS occurs at an early stage of the disease rather than being an end- 
stage event associated with marked disability.
Methodological Considerations
The main limitation of the study was the relatively small sample size and although 
the rate of change in thalamic MTR was significant in patients and not in controls, 
the difference between the rates was not significant. There is therefore a need to 
confirm these findings in a larger cohort. In addition, the limited sample size and the 
use of disease modifying therapy in approximately 30% may account for the absence
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of a significant increase in lesion load, something that has been shown with larger 
cohorts (Sailer et al., 1999). However, the patients in this study do appear to be 
typical of early relapsing-remitting MS patients in terms of relapse rate (The IFNB 
Multiple Sclerosis Study Group, 1993), gender distribution and EDSS. The statistical 
analysis used was prospectively devised on the basis of gender imbalances seen 
between patients and healthy controls and the analysis therefore corrected for any 
effects of possible gender confounding. A correction for multiple comparisons was 
not performed and therefore the results with borderline statistical significance should 
be regarded with caution. The cohort subgroups were too small to allow an 
assessment of whether MTR change was altered by disease modifying treatment. 
However, a significant MTR decrease was seen in the 16 patients who were not 
treated and this supports the finding obtained from the whole cohort in that thalamic 
abnormality emerges early in the natural history of the disease. Finally, it is unlikely 
that thalamic atrophy, during the course of the study, resulted in an artifactual 
reduction of thalamic MTR (via increasing partial volume artifact) because the ROIs 
were positioned to lie entirely within the thalamus and therefore partial volume 
voxels were avoided.
Conclusions
In conclusion, this study found evidence for emerging thalamic MTR abnormality in 
early relapsing-remitting MS, when most patients were non-disabled. As the 
thalamus acts as a central relay point for a number of neuronal pathways, (and as 
some of the thalamic abnormality may be neuronal in origin), these results appear to 
support the view that neuronal abnormality is an early event in the course of the 
disease.
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PART 3
THE ESTIMATION OF UNDERLYING 
MT PARAMETERS
CHAPTER 7 
Estimation of the semi-solid proton fraction and semi-solid T2 in 
multiple sclerosis
As highlighted in Chapter 2, and subsequently in Chapters 4-6, the MTR can provide 
useful, in-vivo, insight into MS pathology. As mentioned, the MTR provides an 
indirect assessment of the semi-solid content of a tissue (van Buchem and Tofts, 
2000; Dousset et al., 1992; Filippi et al., 1995; van Buchem et al., 1996) and in the 
central nervous system, phospholipid bilayers may comprise much of the semi-solid 
proton content (van Buchem and Tofts, 2000; Morrison and Henkelman, 1995). This 
may explain why the MTR is sensitive to changes in both axonal and myelin density 
(van Waesberghe et al., 1999, Schmierer et al., 2004a). However, it appears that the 
MTR is not specific for any single pathological feature, (van Waesberghe et al., 
1999; Gareau et al., 2000), and it is therefore possible that further insight will be 
obtained by estimating the parameters that underlie the MT effect. These parameters 
include the semi-solid proton fraction (/) and the T2 relaxation time of the semi-solid 
pool (T2b). (Further details are given in Chapter 2).
As mentioned, a mathematical model for the magnetization transfer effect, based on 
two pools of protons, has previously been proposed (Henkelman et al., 1993). 
(However, it should be noted that Henkelman’s model describes a system that uses 
continuous wave (CW) irradiation, and this is not directly applicable to the in-vivo 
situation). In the model, the first pool comprises protons in free water with the 
second representing protons within semi-solid structures (such as within 
macromolecules and phospholipid bilayers). The model relates the magnetisation of
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the partially saturated free water to: (1) the relative size of the two pools, (2) 
acquisition specific parameters (including the offset frequency and amplitude of the 
saturating MT irradiation) and (3) a number of rate constants (including longitudinal- 
relaxation, cross-relaxation and absorption rate constants). An adaptation of the 
technique (allowing its’ application to pulsed clinical sequences) has permitted/ and 
T2B to be estimated in human subjects (Ramani et al., 2002; Tozer et al., 2003; Tofts 
et al., 2005). At the time that the study in this chapter was conducted, similar in-vivo 
techniques had been developed by Sled and Pike, (2001) and Yamykh, (2002), but 
while these permitted parameter estimation in a single slice, the technique described 
here (Ramani et al., 2002; Tozer et al., 2003; Tofts et al., 2005) allows for whole 
brain coverage. (Whole brain coverage may be helpful in a diffuse and multifocal 
disease process such as MS). Of note, Yamykh and Yuan (2004) have recently 
developed a technique that also provides whole brain coverage.
The study reported in this chapter used a model for magnetization transfer (MT) to 
estimate the two underlying parameters: /  and T2B in sixty patients with clinically 
definite multiple sclerosis (MS). (This is a different cohort to that described in 
previous chapters). The aims of this study were: (1) to investigate whether 
abnormalities of /  and T2B are present in MS lesions and normal appearing tissues 
and, (2) to explore the relationship of the new measures with clinical status.
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7.1 Theory
The binary spin bath model used for the current study has been adapted from that of 
Henkelman et al. (1993). Henkelman’s model has been outlined in Chapter 2 and 
will not be explained in detail here. A number of adaptations have been made. 
Firstly, Henkelman’s model describes a system that uses a continuous wave (CW) 
field, while on a clinical imager, off-resonance irradiation must be applied as a series 
of MT pulses. Ramani et al., (2002) assumed that their pulse sequence, with an MT 
pulse repeat-time of 41ms, is sufficiently similar (in saturating effect) to a system 
that uses CW irradiation. Under this assumption, the root-mean-square (RMS) of the 
MT pulse amplitude is determined and averaged over the MT pulse repeat time, (this 
is known as the CW power-equivalent: c o c w p e ). It is assumed that an MT sequence 
(with a given c o c w p e ) has the same saturating effect as a CW field that has an 
amplitude equal to c o c w p e  (Ramani et al., 2002; Tofts et al., 2005).
Ramani et al., (2002) reintroduced the MoA term (which was set to unity by 
Henkelman) and included a constant of proportionality (g) (reflecting the gain of the 
amplifier and other scanner settings). The parameter, gMoA (which is equivalent to 
the proton density of free water) is now fitted independently and the expression (see 
over) provides an estimate of signal intensity (S). The model therefore takes the form 
as laid out on the following page. The similarity to Henkelman’s original model can 
be appreciated by comparing this formula with formula [12] in Chapter 2. M<jB has 
also been replaced with/M o A/( l - / ) ,  where/is the semi-solid proton fraction:
/ =  M0b / M0a + M0b
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A final consideration is the absorption line shape for the semi-solid pool (R r fb ) -  
(This is the rate that the semi-solid pool absorbs magnetisation for any given off-set 
frequency). R r fb  depends on the T2 of the semi-solid pool (T 2b ) and by fitting R r fb ,  
(via T2b), a value for T2B can be obtained. Generally the shorter the T2 the broader 
the line shape.
Although Henkelman initially used a Gaussian line shape to model MT in agar, the 
Gaussian proved to be inaccurate for biological tissue. The super-Lorentzian line 
shape (which is expected to arise from partially ordered materials, for example,
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polymers, liquid crystals or biological membranes) allowed for better fits in 
biological material (Morrison and Henkelman, 1995). The super-Lorentzian line 
shape was therefore adopted for the present work (Tofts et al., 2005; Tozer et al.,
2002). The integral describing the super-Lorentzian line shape can be seen in: 
Morrison and Henkelman, (1995).
In the present study, 10 data points are acquired (using differing MT pulse 
amplitudes (each with a corresponding © c w p e )  and differing off set frequencies -  see 
Table 7.1) and the model is fitted to the resulting signal intensities. In the least square 
fitting, five fitted parameters are estimated: gMoA, R M oA, >/7(1-/)R a , 1/R aT2a, and T2B 
(via R r f b )  since it is not possible to independently fit all eight parameters. R b  is fixed 
at Is '1 as the change in sum of squares with respect to Rb was zero. This means that 
R b may take any value without changing the quality of fit and if R b  is unconstrained 
the model will not meaningfully converge. This is in accordance with Henkelman et 
al., (1993) who concluded that Rb could not be determined in such experiments. A 
value of 1 s*1 was selected since this was the value previously assumed, (Morrison and 
Henkelman, 1995; Sled and Pike, 2001) allowing data from this study to be 
compared more easily with data from previous work.
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Table 7.1: The continuous-wave-power-equivalents ( c o c w p e ) and off set frequencies 
(A) of the 10 acquired data points.
®cwpe (rad s *) A (Hz)
185 1000
185 2500
185 7500
378 1000
378 3500
378 15000
435 1000
435 2500
435 5000
435 7500
/ can then be calculated from by firstly obtaining an independent estimate
of the observed Tj: (TiAobs ie.: l/RAobs) -  (this is estimated using a previously 
described method (Parker et al., 2001) -  see Chapter 3 for details) -  and RA can then 
be estimated according to the following relationship (for a derivation of this see 
Henkelman et al., 1993):
* A  =
RAobs
1 +
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7.2 Methods.
Patients and Controls
Sixty subjects with clinically definite MS, (Poser et al., 1983) [38 female and 22 
male; mean age 47 years, range 27 to 73 years; 27 with relapsing remitting (RRMS), 
eight with benign (BMS), 12 with primary progressive (PPMS) and 13 with 
secondary progressive MS (SPMS), (Lublin and Reingold, 1996)] and 27 healthy 
control subjects (13 female and 14 male; mean age 35 years, range 23 to 52 years) 
were studied. (Table 7.2). As there was a large age difference between controls and 
the MS group, comparisons between MS patients and controls were made using only 
those patients aged less than 50. The demographics of this subset were as follows: 18 
female, 15 male; mean age 39, range 27 to 50 years; 22 with RRMS, one with BMS, 
six with SPMS and four with PPMS. In subjects affected by MS, the expanded 
disability status scale (EDSS) score, (Kurtzke, 1983) and the MS functional 
composite scores (MSFC), (Fischer et al., 1999) were determined.
The study was approved by the joint ethics committee of the Institute of Neurology 
and the National Hospital for Neurology and Neurosurgery. All subjects gave 
informed written consent prior to the study.
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Table 7.2: EDSS and disease duration in the full patient cohort and in the four 
clinical subgroups.
N Median EDSS 
(range)
Mean disease 
duration/ years 
(range)
Full MS cohort 60 3.0(1.0-7.5) 15(0.5-38)
Relapsing-remitting MS 27 2.0(1.0-5.0) 9 (0.5-27)
Benign MS 8 2.5 (2.0-2.5) 23 (19-32)
Secondary progressive MS 12 6.0 (3.5-7.5) 24 (5-38)
Primary progressive MS 13 6.0 (2.0-7.0) 12(9-21)
M RI acquisition
Imaging was performed on a 1.5 Tesla Signa scanner (General Electric, Milwaukee, 
USA).Three sequences were acquired in all subjects. 1) A dual echo fast spin echo 
(FSE) sequence (repetition time (TR) 2000ms, echo times (TE) 19/95ms, 28 
contiguous 5mm axial slices covering the whole brain). 2) A MT sequence consisting 
of a Gaussian MT pulse (duration 14.6ms) applied before each slice of a 2D spoiled 
gradient echo sequence (TR 1180ms, TE 12ms, excitation flip angle 25°, field of 
view (FOV) 24x18cm2, slice thickness 5mm; (a line of k-space is acquired from each 
of the 28 slices in one TR). To minimize acquisition time a partial k-space 
acquisition was used, collecting 48 phase encode steps to one side of k = 0 and 8 to 
the other; this was reconstructed to a 256x256 matrix over a 24x24cm2 FOV). The 
interval between the start of successive MT pulses (TR') was 41ms. Ten independent
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measurements each consisting of 28 contiguous oblique axial slices covering the 
whole brain were made at differing MT pulse offsets and powers, (See Table 7.1) 
(Ramani et al., 2002; Tofts et al., 2005) 3) PD and Ti weighted gradient echo data 
sets (TR/TE/flip-angle/no.-of-averages: 1500ms/1 lms/45°/8 and 50ms/llms/45°/2 
respectively) permitting the calculation of Tj relaxation time (Parker et al., 2001). 
(As mentioned, an independent measurement of the observed T\ relaxation time is 
required in order for/to  be estimated). Total scan time was 1 hour.
Image processing
The first MT data set was used as a template to which the FSE images were 
registered (using the AIR package) (Woods et al., 1993). The calculated Ti 
relaxation map and other 9 MT data sets were also registered to this template using 
mutual information registration (Studholme et al., 1999). Lesions were then 
contoured on the FSE data set using Displmage (Plummer, Dept of Medical Physics 
and Bioengineering, UCL, UK) according to previously defined rules (Sailer et al., 
1999). Fourteen normal appearing white matter (NAWM) regions and six normal 
appearing grey matter (NAGM) regions of interest (ROI) were also outlined on the 
first MT data set, with care taken to avoid lesion ROIs. ROIs in normal appearing
' i
regions were cylindrical and had a volume of 130 mm in the corpus callosum and 
internal capsule and 230 mm3 elsewhere. The following regions were outlined 
bilaterally in NAWM: frontal and occipital lobes, anterior and posterior limbs of the 
internal capsule, centrum semiovale and middle cerebellar peduncles. Single mid-line 
regions were outlined in the genu and splenium of the corpus callosum (Figure 7.1 
illustrates some of the white matter ROIs). In grey matter, bilateral regions were
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placed in the thalamus, the caudate and the lentiform nucleus. Cortical grey matter 
regions were not used as partial volume artefact could not confidently be excluded.
Figure 7.1: Regions of interest in a normal control placed (from top) in: frontal white 
matter, genu of the corpus callosum, anterior and posterior limbs of the internal 
capsule, splenium of the corpus callosum and occipital white matter.
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The ROIs defined were then transferred to the 10 (co-registered) MT data sets and 
the Ti map, and the model was fitted to values thus determined. Five fitted 
parameters were estimated: gM0A, RM0A, 1/RAT2A, and T 2b (via R r f b  ) .
Fitting was achieved with a least squares technique based on a Numerical Algorithms 
Group routine, (Ford et al., 1979) and /  was calculated from f!(\-f)RA using the 
observed T\, (which is related to RA) (Henkelman et al., 1993). RB (the longitudinal 
relaxation rate constant of the bound pool) was fixed at Is '1.
A super-Lorentzian line shape was assumed for the absorption line shape of the 
bound pool (Morrison and Henkelman, 1995). The average of the root mean square 
residuals for parameter fitting in NAWM (patients and controls combined) was 1.2% 
(range 0.8% to 2.1%).
The same analysis was performed on a pixel by pixel basis in a single subject and the 
resulting parameters maps can be seen in Figure 7.2.
Statistical Analysis
Group comparisons, were made using the Mann Whitney U test (SPSS 11.0). Control 
and MS patient comparisons were made using a subset of patients below the age of 
50 which allowed for better age and gender matching. The relationships between 
parameters (all 60 MS patients) were assessed using Spearman’s rank correlation 
coefficient (rs). The coefficient of variation was used as a measure of repeatability, p 
values of < 0.05 were regarded as significant.
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7.3 Results.
Reproducibility
Five controls were imaged twice (mean time from scan to rescan was 42 weeks; 
range 21-70 weeks) and coefficients of variation for /  and T2B from NAWM were 
5.4% and 4.7% respectively.
Age and Gender effects
There was no gender difference (patients and controls combined) for mean NAWM /  
(p = 0.5), deep grey matter /  (p = 0.6), mean NAWM T2B, (p = 0.8) or deep grey 
matter T2B (p = 0.6). Age was inversely correlated with mean NAWM/ (rs = -0.42, p
< 0.001) and with deep grey matter/ (rs = -0.28, p = 0.01) but not with mean NAWM 
T2B 0's = 0.16, p = 0.13) or deep grey matter T2B (rs = 0.04, p = 0.7).
Comparisons between patients and controls and correlations between parameters:
Findings in lesions
In lesions, mean/ was 4.6 percent units (pu) versus 9.0 pu in control white matter, p
< 0.001. Mean lesion T2B was 11.5 ps versus 10.6 ps in control white matter, p < 
0.001 (See Table 7.3).
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Table 7.3: Lesion characteristics of the MS subgroups
Mean lesion/ Mean lesion T2b Mean lesion T i
(range) / pu (range) / ps (range) / ms
Full MS cohort 4.7 (3.0-6.9) 11.5 (8.7-13.8) 980 (770-1210)
Relapsing-remitting MS 4.9 (3.4-6.9) 11.2 (8.7-13.4) 950 (820-1130)
Benign MS 4.4 (3.4-5.2) 12.1 (11.3-13.8) 1000 (940-1140)
Secondary progressive MS 4.4 (3.0-5.8) 11.6 (9.1-13.5) 1000 (840-1210)
Primary progressive MS 4.8 (3.6-6.5) 11.4 (9.7-13.4) 990 (770-1110)
Findings in NA WM, Deep grey matter and posterior fossa white matter 
In total NAWM, mean /  was 8.0 pu in MS patients versus 9.0 pu in control white 
matter, p < 0.001. /  values from separate white matter regions, deep grey matter 
regions and the cerebellar peduncles are shown in Table 7.4. /  was abnormal in a 
number of the supra-tentorial white matter regions, but not in the middle cerebellar 
peduncles or deep grey matter.
T2b was not significantly increased in total NAWM. T2b values from separate regions 
are also given (Table 7.4) and the only significant increase was seen in occipital 
white matter.
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In total NAWM, (MS patients and controls combined), /  and T2B were inversely 
correlated; rs = -0.58, p < 0.001.
Cross relaxation rate in white and grey matter
The cross relaxation term (RMoA), which provides an indication of the rate of cross 
exchange between the bound and free pools, was found to be uniformly high in all 
regions in MS patients and controls (>105 s'1).
Relationship between T] relaxation time and M T parameters
An estimate of the spin lattice relaxation time (Ti) was required in order for /  to be 
estimated. Data on T1 was derived from NAWM and lesions so that this data could 
be compared with /  and T2B. In comparison to controls, Ti was increased in lesions 
and in NAWM (Table 7.4). An inverse correlation was seen between Ti and/in  total 
NAWM (patients and controls combined); rs = -0.80, p < 0.001 and a positive 
correlation was seen between T2B and Ti; rs = 0.32, p = 0.003.
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Table 7.4: f  T2B and T\ values compared between 33 MS patients and 27 healthy controls.
Region
Lesions1
/ /pu
MS
4.6
Cont
9.0 < 0.001
T2B/ps
MS Cont p
11.5 10.6 <0.001
Ti / ms
MS Cont
970 650 < 0.001
Total WM 8.0 9.0 < 0.001 10.8 10.6 0.39 710 650 < 0.001
Frontal WM 
Genu of CC 
Anterior IC 
Posterior IC 
Splenium of CC 
Occipital WM 
CSO
8.6
8.1
7.0
8.0 
8.4 
7.7 
8.2
9.8
9.5 
7.7 
8.2
9.5
9.1
9.2
0.001
0.002
0.013
0.54
0.002
< 0.001
< 0.001
10.5 
10.8 
11.4 
11.3 
10.0 
11.0
10.6
10.5
10.6 
10.9 
11.6 
9.4 
10.6 
10.5
0.95
0.77
0.24
0.46
0.10
0.03
0.95
680 610 
700 620 
740 710 
730 680 
730 660 
700 630 
690 630
< 0.001
< 0.001
0.06
0.002
< 0.001
< 0.001
< 0.001
Cerebellar Ped. 7.4 7.4 0.99 10.4 10.2 0.52
Total deep GM 4.6 4.7 0.45 10.7 10.6 0.61
Caudate
Lentiform
Thalamus
3.6
4.7 
5.6
3.6 
4.8
5.6
0.16
0.67
0.80
10.8
10.5
10.9
11.1
10.0
10.6
0.61
0.30
0.67
Bold type: significant at p < 0.05 level; 
using Mann-Whitney U test. Cont = values 
from 27 healthy controls, MS = values 
from 33 MS patients. WM = white matter, 
GM = grey matter, CC = corpus callosum, 
CSO = centrum semi ovale, IC = internal 
capsule. Cerebellar Ped. = middle 
cerebellar peduncle. alesions compared to 
total control white matter. b supra-tentorial 
WM pooled.
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T2 lesion load measures
Mean T2 lesion load was 19.3 ml (median 16.3 ml, range 0.5 to 79.3 ml). T2 lesion 
load correlated with NAWM T2B (rs = 0.37, p = 0.004) and was inversely correlated 
with NAWM/ (rs = -0.52, p < 0.001)
Clinical Status and correlations with M T parameters and Tj relaxation time
Median EDSS and mean disease durations for all 60 subjects with MS and for the 
four clinical subgroups are given in Table 7.2. Table 7.5 shows all significant 
correlations between clinical function and MT measures. A modest correlation was 
seen between total NAWM /  and the MSFC. /  also correlated with the MSFC in 
several white matter tracts (the genu and splenium of the corpus callosum, the 
anterior limb of the internal capsule and the cerebellar peduncles). A modest 
correlation was seen in frontal NAWM. The only significant correlation between /  
and the EDSS was seen in the genu of the corpus callosum. T2B showed a modest 
correlation with the MSFC (and EDSS) in the splenium of the corpus callosum 
(Table 7.5). Ti correlated weakly with the MSFC in total NAWM. It also correlated 
with the MSFC and the EDSS in the corpus callosum (Table 7.5).
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Table 7.5. Spearman’s r values for clinical- MR correlations
Region / / p u T2B/p s Ti / ms
EDSS MSFC EDSS MSFC EDSS MSFC
Lesions ns ns ns ns ns ns
Total WM * -0.24 0.43* ns ns ns -0.28
Frontal WM ns 0.30 ns ns ns ns
Genu of CC -0.34* 0.40* ns ns 0.32 -0.34
Anterior IC ns 0.33 ns ns ns ns
Posterior IC ns 0.26 ns ns ns ns
Splenium of CC ns 0.38* 0.28 -0.34 0.24 -0.36*
Occipital WM ns 0.25 ns ns ns ns
CSO -0.24 0.26 ns ns ns ns
Cerebellar Ped. ns 0.28 ns ns
Total deep GM ns ns ns ns
Caudate ns ns ns ns
Lentiform ns ns ns ns
Thalamus ns ns ns ns
Non Bold type: borderline only: p < 0.08. Bold: significant at p < 0.05 level.
Bold* p < 0.01, ns: p > 0.08. WM = white matter, GM = grey matter, CC = corpus 
callosum, CSO = centrum semi ovale, IC = internal capsule. Cerebellar Ped. = 
middle cerebellar peduncle.a supra-tentorial WM pooled.
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Figure 7.2: Parameter maps in a patient with MS. Top row from left to right: PD 
map, T 2b map, J7(UJ)Ra map. Bottom row, left to right: T iA/T 2a map, T iAobs m ap ,/ 
map.
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7.4 Discussion.
In the study of MS, one limitation of conventional MRI is that it lacks the 
pathological specificity seen with histopathological techniques (van Waesberghe et 
al., 1999; Gareau et al., 2000). Consequently, a MR technique that offers greater 
pathological specificity might improve upon the description or the monitoring of in- 
vivo changes. A potential way of achieving this would be to use the magnetisation 
transfer effect to derive a set of underlying parameters which, in turn, provide a more 
detailed description of tissue structure. Such an approach has been attempted here. 
This quantitative analysis of the MT effect yielded two parameters that provide 
complementary information. T2B, a measure of the motional restriction of semi-solicjp' 
protons, is increased in lesions whereas / , a measure of the semi-solid proton to total 
proton ratio, shows more diffuse but clinically relevant abnormality.
Although the nature of the semi-solid proton fraction is uncertain, the improvement 
seen in fitting when the model is altered to more accurately account for the nature of 
phospholipid bilayers, (Morrison and Henkelman, 1995) would suggest that 
phospholipid bilayers are an important component of the semi-solid content in this 
instance. Principle changes within lesions include T-cell mediated inflammation, 
demyelination, (Lassman et al., 1998), axonal loss, (Trapp et al., 1998) and gliosis, 
(Adams, 1977). In NAWM, axonal loss and gliosis (and, to a lesser extent, 
perivascular inflammation and demyelination) have also been demonstrated (Allen 
and Mckeown, 1979; Evangelou et al., 2000). Although /  could be reduced by a 
decrease in the semi-solid content either via demyelination or axonal loss, it should 
also be noted that/ is a ratio of semi-solid protons to total protons and an increase in
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the free water component (as in oedema) could also result in a reduction in f  
Histopathological studies correlating/with pathological findings are now required to 
investigate these relationships.
Correlations were seen between /  and disability, particularly when /  was estimated 
from long white matter tracts (the corpus callosum, the internal capsule and the 
cerebellar peduncles), indicating that the changes detected by this parameter do have 
clinical relevance. These correlations might suggest that long white matter tract 
pathology has a role in the accrual of disability.
T2B was sensitive to pathology within lesions but was much less sensitive to 
abnormality within normal appearing brain tissue. The parameter is an estimate of 
the T2 relaxation time of semi-solid protons and therefore is likely to detect changes 
to the structure of the semisolid content (rather than changes to the semi-solid/ffee 
water ratio). The increase in T2B in lesions suggests that there has been a change in 
the nature of the remaining semi-solids, conceivably due to a disruption of myelin 
and axonal phospholipid bilayers.
The results need to be interpreted in the context of a number of methodological 
considerations. Firstly, although the fitting of the model to experimental data is 
reasonable, (giving some confidence in its validity), the model contains a number of 
assumptions which are only partially met in practice. The assumption of two pools, 
made by both Henkelman and ourselves is, in itself an approximation, and a fuller 
description might include longer and shorter T2 components in both the ‘bound’ and 
‘free’ pools, along with interactions between them. The original model (proposed by
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Henkelman et al, 1993) also describes a system with a continuous saturating power 
and we have therefore made the assumption that our pulse sequence sufficiently 
approximates a continuous power. This might lead to some error in parameter 
accuracy and although /  and T2B were similar when estimated with other models, 
(Sled and Pike, 2001; Yamykh, 2002) it may explain the discrepancy in the rate of 
cross relaxation; (which was uniformly high in our case). A  better estimate of the rate 
of cross-relaxation might allow for a more accurate estimate of f  and, with this in 
mind we are continuing to refine the model and pulse sequence.
Secondly, the statistical analyses used did not correct for multiple comparisons and 
so it is possible that some of statistically significant results occurred by chance. For 
this reason the data has been presented in tabulated form so that the number of 
comparisons (and the proportion that are significant) can be appreciated. The pattern 
of abnormality seen in NAWM and the correlations with disability were similar 
between parameters, adding support to the view that these were biological effects.
The parameter /  appears to be sensitive to abnormality within lesions and normal 
appearing brain tissue and its correlation with disability indicates that it has some 
clinical relevance. However, histopathological post mortem data is now required to 
assess the pathological specificity of /  and T 2b- Imaging techniques that quantify 
demyelination would be of use in following MS pathology (for instance in 
symptomatic demyelinating lesions of the optic nerve or spinal cord) and especially 
in monitoring therapies to promote remyelination. Quantitative MT techniques are 
therefore likely to be the subject of further work, with the aim of refining the 
technique to improve upon specificity for the detection of myelin. Of note, Stanisz et
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al., (2004a, b) have recently found that the relative size of the bound pool (MoB), 
(estimated in rat sciatic nerve), altered in the presence of experimentally induced 
inflammation and demyelination. It will now be relevant to directly correlate /  and 
T2B with post mortem histopathological data and to obtain global in vivo measures 
via histogram analysis.
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PART 4 
CONCLUSIONS
CHAPTER 8 
Conclusions
This thesis describes a number of studies that have investigated the changes within 
the normal-appearing brain tissue in patients with early relapsing-remitting MS. One 
objective was to describe the early evolution of abnormality within the normal- 
appearing white matter and grey matter, prior to the onset of major disability. At the 
time that the studies in this thesis were conducted, it was unclear whether 
abnormalities within the normal-appearing white matter (NAWM), the cerebral grey 
matter, and the thalamus progressively accumulated in early disease and at what 
stage such abnormalities began.
In the context of clinical trials, measures that detect abnormality within grey matter 
and NAWM, have the potential to improve the effectiveness of MRI surrogate 
endpoints. As discussed in Chapter 2, a key requirement of any surrogate is that it 
should be strongly predictive of long term disability (McFarland et al., 2002), and 
that it should be sensitive to change over time prior to the onset of disability. Brain 
T2 lesion load is a widely used measure, used to follow the course of the disease; and 
-  in clinical trials -  to evaluate treatment efficacy; however, although it can detect 
change over time in early MS (Sailer et al., 1999), it is only modestly predictive of 
long term disability (Brex et al., 2002). Possible reasons for this modest correlation 
include: (1) that lesions are pathologically heterogeneous, (2) that lesions vary in 
their anatomical distribution (and hence clinical relevance), and (3) that lesion 
accrual in early disease may have a greater effect on disability accumulation than 
lesion accrual in late MS. However, a further potential reason for the modest
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correlation is that changes within grey matter and NAWM are also contributing to 
later disability. By quantifying these changes (and by combining them with lesion 
load measures), it may be possible to develop surrogate endpoints which are more 
strongly predictive of future clinical impairment. Hypothetically, such measures 
could provide useful insight into which therapies have potential to prevent long term 
disability (and so provide guidance into which therapies should be further 
investigated using clinical endpoints). However, prior to concluding that a measure 
of early abnormality in grey matter and NAWM could usefully contribute as a 
surrogate endpoint, it is necessary to show that such measures are strongly predictive 
of future clinical impairment. At present, the long term data necessary to show this is 
not available and further follow-up of the cohort is required. This thesis has therefore 
focussed on another key question: namely whether these measures are sufficiently 
sensitive and reproducible to detect a change over time in minimally-disabled 
patients with early relapsing-remitting MS.
In a clinical trial, a treatment effect is likely to manifest as a difference in the rate at 
which abnormalities accumulate, when the placebo and treatment groups are 
compared. Therefore, if measures of normal-appearing tissue abnormality are to be 
useful, they must be able to detect increasing abnormality over the 2-3 year time 
frame typical of many trials. Although many measures, (including clinical ones), can 
detect increasing abnormality in progressive MS, measures which can also detect 
increasing abnormality prior to the onset of progressive disability may be particularly 
useful. As discussed in Chapter 1, once clinical progression has commenced, a self- 
propagating pathological deterioration may occur, and at this stage, disease-
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modifying treatments are likely to be less effective (or not at all effective). 
Furthermore, once permanent disability has occurred, it may be very difficult to 
reverse. Measures therefore that can detect increasing and clinically relevant grey 
matter and NAWM abnormality, early in the disease course, could be useful. In all, 
the ideal surrogate would provide a complete assessment of accumulating 
pathological abnormality in early MS (encompassing measures of grey matter and 
NAWM abnormality); it should be sensitive and specific for the pathological changes 
that lead to later disability, and it should be strongly predictive of later clinical 
impairment. Finally the measure should be sufficiently sensitive and reproducible to 
detect increasing change over a 2-3 year time frame in patients with early MS and 
minimal disability.
Prior to the studies included in this thesis, two measures showed particular promise 
for investigating normal-appearing brain tissue abnormality. These were: the MTR 
and, the related measure, the T\ relaxation time. Ti measurement is able to detect 
grey matter and NAWM abnormality in early relapsing-remitting MS (Griffin et al., 
2002b) and Ti measured globally, throughout the brain, shows an association with 
the mild clinical impairments already present (Griffin et al., 2002a). Furthermore, a 
study of patients with more advanced disease (including some with secondary 
progressive MS) reported that Ti histograms were sufficiently sensitive to detect 
increasing abnormality over a 20 month period (Parry et al., 2003). Therefore, in 
Chapter 3, the objective was to assess whether grey matter and NAWM Ti 
histograms were sufficiently sensitive and reproducible to detect a change over time 
in patients with early relapsing-remitting MS. As discussed in Chapter 3, there was
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no strong evidence that Tj measures (acquired using a two-point non-interleaved 
technique), were able to detect such a change. Although there was borderline 
evidence for a decline in patient NAWM peak-height, there was no serial change in 
either mean T i or peak-location. Although these findings may have arisen because 
the peak-height may be more sensitive than either the mean or the peak location, it 
should also be noted that peak-height had limited reproducibility in comparison to 
other parameters, making it potentially less useful. Reasons for the poor 
reproducibility include the possibility that peak-height might fluctuate with 
inflammatory activity; (it should be recalled that, in Chapter 3, patient peak-height 
COV was more than double that of control peak-height COV; in addition, previous 
studies have shown that Ti is sensitive to changes in cerebral oedema). In all, there 
was no conclusive evidence that grey matter and NAWM Ti histograms were able to 
detect a change over time in early relapsing-remitting MS. There appears to be two 
possible reasons for this finding. Firstly, a measure derived from a two-point non­
interleaved technique may be insufficiently reproducible to allow a subtle serial 
change to be detected. Secondly, the Ti relaxation time appears to be a non-specific 
measure; and although it may detect pathologies that might gradually worsen (such 
as axonal loss), it may also detect reversible pathology (such as inflammatory 
activity) which may fluctuate rather than progressively deteriorate.
In Chapters 4 and 5, attention was turned to the use of MTR in early relapsing- 
remitting MS. The extensive literature on MTR reveals that the parameter may be 
semi-specific for changes in myelin and axonal density (with smaller changes seen 
with inflammation). As a result, MTR might be more effective than Ti at detecting
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increasing structural abnormality (that reflects the loss of axons and/or myelin) in 
early MS. Furthermore, the MTR sequence used in this work was interleaved, 
potentially making it less prone to the short term changes in scanner gain (Jackson et 
al., 2004) which may have contributed to the limited reproducibility of Ti. However, 
prior to conducting the studies of MTR, there was uncertainty whether the technique 
was able to detect grey matter abnormality in early MS. One earlier study had shown 
that grey matter MTR was abnormal in patients with CIS suggestive of MS 
(Traboulsee et al., 2002); but a further study, investigating the present cohort using a 
region of interest approach, did not find evidence for grey matter MTR abnormality 
(Griffin et al., 2002b). In Chapter 4, the objective was therefore to obtain a more 
complete assessment of grey matter MTR in early relapsing-remitting MS, using 
MTR histograms. This study revealed that both grey matter and NAWM MTR were 
abnormal in the cohort, and that MTR abnormality within grey matter (as opposed to 
abnormality within white matter) was associated with the mild clinical impairments 
already apparent.
Chapter 5 extended the observations reported in Chapter 4 by presenting serial data 
on a subset of patients who had been followed up for ~2 years. This study revealed 
that grey matter and NAWM MTR abnormality continued to increase during the two 
years of the study. The rates of change were not related to relapse frequency, nor to 
changes in T2 lesion load. Furthermore, the rate of change in grey matter was 
significantly greater than the rate of change in white matter. (In this analysis, brain- 
parenchymal-ffaction was included as a covariate and so differences in rate would be 
unlikely to be secondary to the effects of atrophy). Furthermore, backward
172
extrapolation of the data -  under the assumption that the rate of change was linear - 
suggested that (i) NAWM MTR abnormality began prior to symptom onset and (ii) 
grey matter abnormality began around the time of the first episode (which was 
significantly later than the onset of white matter abnormality). However, it should be 
noted that early changes in grey matter and NAWM may be non-linear and thus have 
a different dynamic to that suggested by the extrapolations. Although it appears 
reasonable to conclude (from inspection of the raw data plots) that increasing 
abnormalities are genuinely occurring in both tissues, caution should nonetheless be 
used when interpreting the result. The cohort was relatively small, and although it 
appeared to be representative (in terms of relapse rate, EDSS and disease duration), 
confirmation of these results in a larger cohort is now needed.
The results from Chapters 4 and 5 revealed that MTR was a useful technique in the 
study of early relapsing-remitting MS. Attention was therefore turned to the study of 
the thalamus using MTR, particularly as investigation of thalamic abnormality may 
provide useful insight into neuronal/axonal abnormality in early MS. Furthermore, a 
number of recent studies have reported thalamic abnormality in patients with 
established secondary progressive and relapsing-remitting MS. At the time that the 
study was conducted, it was unclear whether thalamic abnormality developed in 
early MS, or whether it was a feature that developed following the onset of major 
disability. In Chapter 6, details on a study investigating thalamic MTR in early 
relapsing-remitting MS patients were presented. The results indicated that thalamic 
MTR became abnormal during the first five years of clinical disease. There was also 
an association between baseline lesion volume and the degree of thalamic MTR 
abnormality subsequently observed; however, there was no significant cross-
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sectional correlation between baseline lesion volume and baseline thalamic MTR. In 
interpreting the results, it is possible that some of the thalamic MTR abnormality 
observed resulted from the Wallerian degeneration of axons transected in lesions, 
thus accounting for the temporal dissociation between baseline lesion volume and 
thalamic MTR. However, before concluding that thalamic MTR abnormality relates, 
in part, to the Wallerian degeneration of axons, confirmation of these findings in a 
larger cohort is required.
Implications fo r understanding the pathogenic mechanisms in early RRMS
In summary, Chapters 3-6 have provided evidence for accumulating abnormality 
within NAWM and grey matter in early relapsing-remitting MS. While a number of 
previous studies have reported NABT abnormality early in the course of the disease, 
some additional features have been highlighted by the present work: Firstly, evidence 
has been presented for grey matter MTR abnormality in early relapsing-remitting MS 
- supporting the prior observation of grey matter MTR abnormality in CIS patients 
(Traboulsee et al., 2002). Secondly, an extrapolation of the serial data suggests that 
NAWM MTR abnormality predates symptom onset, (and that this change begins 
before the changes in grey matter). Thirdly, NAWM and grey matter MTR 
abnormalities increase over time in early MS, and this suggests that clinically-silent 
and progressive abnormalities are occurring in both tissues at an early stage of the 
disease. As there is a limited relationship between lesion load and long term 
disability, it appears reasonable to speculate that these early, progressive changes 
have a role to play in MS pathogenesis, and that they might have an effect upon long 
term prognosis.
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Questions remain regarding the pathological basis for the observed MTR 
abnormalities. As mentioned, in Chapter 2, demyelination and axonal loss may result 
in a reduced MTR, with smaller reductions seen with inflammation. The pathological 
abnormalities observed in MS NAWM - at post-mortem - include axonal loss 
(Evangelou et al., 2000a), some of which could result from the Wallerian 
degeneration of axons transected in acute inflammatory lesions (Trapp et al., 1998). 
Of note, axonal transection has been shown to occur at an early stage of the disease 
(Kuhlmann et al., 2002), and a reduction in NAWM N-acetyl-aspartate (a neuronal 
marker) has previously been reported in early relapsing-remitting MS (Chard et al., 
20026). Axonal degeneration could therefore be one explanation for the 
accumulating NAWM MTR abnormalities observed. However, it should be noted 
that a number of other pathological abnormalities (including gliosis, microglial 
activation, patchy demyelination and peri-vascular inflammation) have been reported 
(Allen and McKeown, 1979; Allen et al., 2001); and previous studies have observed 
an increase in myo-inositol concentrations, (suggestive of glial proliferation), in early 
relapsing-remitting MS and CIS suggestive of MS (Chard et al., 20026; Fernando et 
al., 2004). Some of these additional processes could therefore also be contributing to 
the MTR abnormalities observed.
Lesions within grey matter, [which are typically less inflammatory than white matter 
lesions (Peterson et al., 2001) and often less MR visible (Kidd et al., 1999)], are 
associated with demyelination and axonal loss (Peterson et al., 2001). Both of these 
changes could account for the grey matter MTR changes observed. Furthermore, it is 
conceivable that an accumulation of grey matter lesions and the degeneration of 
transected axons could account for the progressive decline in grey matter MTR seen 
in the cohort.
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Estimation o f the underlying MT parameters
Although MTR has been used widely in the study of MS, additional information 
could be obtained by estimating parameters that underlie the MT effect. These 
include the semisolid proton fraction (/) and the T2 of the semisolid pool (T2b). In 
Chapter 7, these parameters were estimated using a model for the MT effect, in sixty 
patients with clinically-definite MS. The parameter /  was abnormal in lesions and 
NAWM, while T2B was only abnormal in lesions. NAWM/ was also associated with 
disability. It remains uncertain whether these parameters are able to provide 
pathologically specific information and a correlation of /  and T2B with 
histopathological data now needs to be performed. However, the technique is likely 
to be the subject of future work and with further refinement of the model and 
sequence it may be possible to improve upon specificity for the detection of myelin.
Conclusion
In conclusion, the MTR has provided useful insight into the pathological processes 
that occur in the NAWM and grey matter in patients with early relapsing-remitting 
MS. The MTR is able to detect increasing abnormality in both tissues over a two 
year follow-up period, and it is possible that these early and progressive pathological 
changes have a role to play in the pathogenesis of MS. There is therefore an 
argument for performing further serial MTR investigation in patients participating in 
natural history studies or in treatment trials. If the evolving changes are shown to 
correlate with later disability, the MTR might -  in the future -  be adopted as a 
reliable surrogate measure of disease progression.
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Appendix
The technique used to segment tissue into NAWM and grey matter was adapted from 
previous work (Chard et al., 2002c; Traboulsee et al., 2002) in collaboration with Dr 
Andreas Hadjiprocopis. In brief, Statistical Parametric Mapping 1999 (SPM99) 
(Ashbumer and Friston, 1997, 2000) was used to segment raw images (namely: T2 
weighted images for the MTR analysis and Ti weighted images for Ti measurement) 
into grey matter and white matter. The segmentation tool in SPM99 uses prior 
anatomical information and a clustering algorithm to estimate probability maps for 
white matter, grey matter and CSF (Ashbumer and Friston, 1997, 2000). Whole brain 
masks were then generated in SPM99, using the grey matter and white matter 
probability maps, and these masks were used to remove non-brain parenchyma from 
the Ti and MTR maps (See Figure A.l on next page).
Next, the whole brain maps were segmented onto grey matter, white matter and CSF 
using the three SPM99 probability outputs. (Voxels were classified as belonging to a 
particular tissue depending upon which probability map showed the greatest 
probability at that location -  See Figure A.2 on page 159).
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Figure A.I. Grey matter, white matter and CSF probability maps from a control 
subject (above). The grey matter and white matter probability maps are combined to 
create a whole brain mask (middle left) and this is applied to the MTR map (middle 
right) to remove non-brain parenchyma (below).
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Figure A.2. The SPM probability outputs are used to segment the whole brain MTR 
map into grey matter and white matter. Following the application of a lOpu 
threshold, two voxel erosions are performed in white matter and single erosion is 
performed in grey matter (see text below).
Following tissue segmentation, the pixel value of lesions was set to zero to leave 
only NAWM and NAGM. Thresholds were then applied to both the Ti and MTR 
maps to further minimize the number of misclassified voxels. Following a pilot study 
of five MS patients and six healthy control subjects, (in which the Ti values of white 
matter and grey matter were ascertained), a 1000ms threshold was applied to white 
matter (which minimized both grey matter and CSF containing voxels), and a 
1700ms threshold was applied to grey matter (to minimize CSF). With the MTR 
analysis, a threshold of lOpu was applied to both grey matter and the white matter; 
(the same threshold was used for both tissues as there was only a 6pu difference 
(range 3pu-9pu) between the mean grey matter and mean white matter MTR). To 
further reduce the number of partial volume voxels, inner and outer voxel erosions 
were performed; two erosions were performed in white matter and a single erosion 
was performed in grey matter; (visual inspection of the grey matter maps revealed 
that, with two or more erosions, only limited numbers of grey matter voxels 
remained). The effect of sequential erosions on white matter and grey matter Tj 
values in five MS patients and six controls is shown below.
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Figure A.3. The effect of sequential erosions on white matter and grey matter in five 
MS patients and six healthy controls. The white matter Tj falls, possibly because of 
the elimination of grey matter and CSF containing voxels. The grey matter Ti 
initially rises, possibly because of elimination of white matter containing voxels. It 
should be noted that the erosions do not appear to effect patient-control differences.
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Validation of Segmentation Algorithm in MS
In order to ascertain the effect that MS lesions might have upon tissue segmentation, 
simulated lesions were placed within the brain images of healthy controlled subjects 
(Figure A.4).
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Figure A.4. Simulated lesions placed with the white matter of a healthy control. The 
signal intensity is set at a value mid-way between grey matter and CSF signal 
intensity, (which approximates the average signal intensity of MS lesions - see text 
below).
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Initially, (in a single healthy control), 15ml of simulated lesions were positioned 
within the T2 image subsequently used for tissue segmentation. Simulated lesions 
were arranged in a periventicular distribution within the cerebral white matter. In a 
series of separate experiments, the signal intensity of the simulated lesions was 
varied (relative to the WM, GM and CSF signal intensity) and the effect on white 
matter and grey matter MTR ascertained. Results are illustrated in the graphs (Figure 
A. 5a) below.
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Results revealed that the observed MTR values deviated from the true tissue values 
in a manner dependent on the simulated lesion signal intensity. The observed peaks 
(seen mostly clearly with grey matter) correspond to the average signal intensity of
183
white matter, grey matter and CSF. In the 38 patients (described in Chapter 4), the 
average signal intensity of lesions was then evaluated. This was found to 
approximate the mid-point between grey matter and CSF signal intensity and 
therefore this was the value selected for the second experiment (in which the 
simulated lesion load was sequentially increased in a single healthy control subject). 
The results of this are illustrated in the following graphs (Figure A.5b):
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In the last experiment, 15 ml of simulated lesions were added, in a periventricular 
distribution, to the 35 healthy control subjects detailed in Chapter 4, (the mean lesion 
volume of the 38 patients was 14.9ml). Grey matter and white matter signal intensity 
were assessed (via a region of interest approach) and the signal intensity of the 
simulated lesions set at the mid-point between grey matter and CSF signal intensity.
The effect was to increase the control WM MTR value by, on average, 0.03pu and 
decrease the GM MTR value, by 0.09pu. A cross-sectional comparison between 
patients and controls, (using the control values obtained following insertion of 
simulated lesions), was undertaken. As in Chapter 4, the comparison was made using 
a linear model which included gender as a fixed factor and age as a continuous 
covariate. The grey matter MTR difference between patients and controls remained 
significant at p = 0.004; (the difference in white matter was also significant at p < 
0 .001).
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